CLINICAL TRIAL REPORT  ZP4207-17086 ( ZEA-DNK-02170) 
 
 Section 16.1.9: Documentation of Statistical Methods  16.1.9 DOCUMENTATION OF STATISTICAL METHODS 
 
This appendix includes 
 
Document  Date , Version  
Statistical Analysis Plan  Version 1.0 Date  16 August 2019  
 

 
TMP-SOP- 0202- 001-03_SAP Template  Page 1/ 110 
CONFIDENTIAL 
ZEA- DNK -02170_SAP_Vers.1.0_clean_16AUG2019.docx 
 
 
 
Statistical Analysis Plan 
 
Sponsor: Zealand Pharma A/S 
Protocol Number ZP4207-17086 (ZEA-DNK-02170) 
 
Study Title: 
A phase 3, randomized, double-blind, placebo- and active-controlled, parallel-arm trial to 
assess the eff
icacy, safety, and pharmacokinetics of dasiglucagon relative to placebo and 
GlucaGen® when administered as a rescue therapy for severe hypoglycemia in children 
with T1DM treated with insulin 
Protocol Version 3.0: 08 January 2019 
 
 
 
Sponsor:
   Zealand Pharma A/S 
   Smedeland 36  
   2600 Glostrup, Copenhagen 
   Denmark 
 
 
Prepared by:  , Synteract  
Albrechtstr.14, 80636 Munich, Germany  
 
 
Version  Date  
Draft 0.1  10APR2019  
Draft 0.2  06JUN2019  
Draft 0.3  14JUN2019  
Draft 0.4  28JUN2019  
Draft 0.5  17JUL2019  
Draft 0.6 – pre-final version  22JUL2019  
1.0 16AUG2019  




 
Zealand Pharma A/S   Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)  16 August 2019  
 
TMP -SOP -0202 -001-03_SAP Template  Page 3/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  TABLE OF CONTENTS  
 
LIST OF ABBREVIATION S ................................ ................................ ................................ ................................ ........  5 
1. INTRODUCTION  ................................ ................................ ................................ ................................ ............  7 
2. STUDY DOCUMENTS  ................................ ................................ ................................ ................................ ..... 7 
3. STUDY OBJECTIVES  ................................ ................................ ................................ ................................ .......  7 
3.1 PRIMARY OBJECTIVE  ................................ ................................ ................................ ................................ .................  7 
3.2 SECONDARY OBJECTIVE  ................................ ................................ ................................ ................................ .............  7 
4. STUDY DESIGN AND PLA N ................................ ................................ ................................ .............................  7 
5. DETERMINATION OF SAM PLE SIZE  ................................ ................................ ................................ ................  8 
6. GENERAL ANALYSIS CON SIDERATIONS  ................................ ................................ ................................ .........  9 
7. NOTATION OF TREATMEN T GROUPS AND VISITS  ................................ ................................ ........................  10 
8. ANALYSIS SETS  ................................ ................................ ................................ ................................ ............  10 
9. STUDY POPULATION  ................................ ................................ ................................ ................................ ... 11 
9.1 PATIENT DISPOSITION  ................................ ................................ ................................ ................................ .........  11 
9.2 PROTOC OL DEVIATIONS  ................................ ................................ ................................ ................................ .......  11 
9.3 ELIGIBILITY  ................................ ................................ ................................ ................................ ........................  11 
9.4 DEMOGRAPHIC AND BASELINE CHARACTERISTICS  ................................ ................................ ................................ ...... 12 
9.5 CONCOMITANT MEDICATIONS AND CURRENT DIABETES TREATMENT  ................................ ................................ ...........  13 
10. EFFICACY ANALYSES  ................................ ................................ ................................ ................................ .... 13 
10.1 EFFICACY VARIABLES  ................................ ................................ ................................ ................................ ...... 14 
10.2 BASEL INE VALUES  ................................ ................................ ................................ ................................ ..........  14 
10.3 ADJUSTMENTS FOR COVARIATES  ................................ ................................ ................................ .......................  14 
10.4 HANDLING OF DROPOUTS OR MISSING DATA ................................ ................................ ................................ ...... 14 
10.5 INTERIM ANALYSIS AND DATA MONITORING  ................................ ................................ ................................ .......  14 
10.6 EXAMINATION OF SUBGROUPS  ................................ ................................ ................................ .........................  15 
10.7 MULTIPLE COMPARISON /MULTIPLICITY  ................................ ................................ ................................ .............  15 
10.8 MULTICENTER STUDIES  ................................ ................................ ................................ ................................ ... 15 
11. METH ODS OF EFFICACY ANAL YSIS  ................................ ................................ ................................ ..............  15 
11.1 PRIMARY EFFICACY ANALYSES  ................................ ................................ ................................ ..........................  15 
11.2 SECONDARY EFFICACY ANALYSES  ................................ ................................ ................................ ......................  18 
12. PHARMACOKINETIC ANAL YSES  ................................ ................................ ................................ ...................  18 
12.1 DATA HANDLING  ................................ ................................ ................................ ................................ ...... 19 
12.2 PRESENTAT ION OF PLASMA CONCENTRATIONS AND PK METRICS  ................................ .............................  20 
13. PHARMACODYNAMIC ENDP OINTS  ................................ ................................ ................................ .............  21 
14. SAFETY ANALYSES  ................................ ................................ ................................ ................................ .......  22 
14.1 EXTENT OF  EXPOSURE ................................ ................................ ................................ ................................ ..... 22 
14.1.1  INSULIN ADMINISTRATIO N PRIOR TO THE HYPOG LYCEMIA INDUCTION PR OCEDURE  ................................ ..................  22 
14.1.2  HYPOGLYCEMIA INDUCTIO N PROCEDURE  ................................ ................................ ................................ .......  22 
14.1.3  TRIAL MEDICATION ADMI NISTRATION  ................................ ................................ ................................ ............  22 

 
Zealand Pharma A/S   Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)  16 August 2019  
 
TMP -SOP -0202 -001-03_SAP Template  Page 4/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  14.1.4  POST-TREATMENT RESCUE GLU COSE INFUSION  ................................ ................................ ................................  23 
14.2 LOCAL TOLERABILITY  ................................ ................................ ................................ ................................ ...... 23 
14.3 ADVER SE EVENTS ................................ ................................ ................................ ................................ ...........  24 
14.3.1  SUMMARY OF ADVERSE EV ENTS  ................................ ................................ ................................ ...........  24 
14.3.2  ADVERSE EVENT TABLES  ................................ ................................ ................................ ......................  25 
14.4 CLINICAL LABORATORY EVALUATION  ................................ ................................ ................................ .................  26 
14.4.1  GENERAL  ................................ ................................ ................................ ................................ ..............  26 
14.4.2  HEMATOLOGY  ................................ ................................ ................................ ................................ ...... 27 
14.4.3  BIOCHEMISTRY  ................................ ................................ ................................ ................................ ..... 27 
14.4.4  COAGULA TION ................................ ................................ ................................ ................................ ...... 27 
14.4.5  URINALYSIS  ................................ ................................ ................................ ................................ ..........  27 
14.4.6  PREGNANCY TEST  ................................ ................................ ................................ ................................ . 27 
14.4.7  ALCOH OL BREATH TEST ................................ ................................ ................................ ........................  27 
14.5 VITAL SIGNS ................................ ................................ ................................ ................................ .................  27 
14.6 PHYSICAL EXAMINATION  ................................ ................................ ................................ ................................ . 27 
14.7 ELECTROCARDIOGRAM  ................................ ................................ ................................ ................................ .... 27 
14.8 IMMUNOGENICITY  ................................ ................................ ................................ ................................ .........  28 
15. CHANGES TO PROTOCOL -SPECIFIED ANALYSES  ................................ ................................ ...........................  28 
1. REFERENCES  ................................ ................................ ................................ ................................ ...............  29 
2. APPENDICES  ................................ ................................ ................................ ................................ ...............  30 
APPENDIX A: PRESENTATION OF DATA AND PROGRAMMING SPECIFICATIONS  ................................ ................................ ..........  30 
APPENDIX B: SAS  PROGRAMMING QC REQUIREMENTS  ................................ ................................ ................................ ...... 33 
APPENDIX C:  LIST OF TABLES , FIGURES , AND LISTINGS  ................................ ................................ ................................ ........  36 
SECTION 14: TABLES , FIGURES , AND GRAPHS  ................................ ................................ ................................ ....................  36 
SECTION 16.2:  LIST OF DATA LISTINGS  ................................ ................................ ................................ ............................  42 
APPENDIX D: TABLE LAYOUTS  ................................ ................................ ................................ ................................ ........  45 
APPENDIX E: LISTING LAYOUTS  ................................ ................................ ................................ ................................ ..... 110 

 
Zealand Pharma A/S   Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)  16 August 2019  
 
TMP -SOP -0202 -001-03_SAP Template  Page 5/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  LIST OF ABBREVIATION S 
 
ADA  anti-drug antibody  
AE adverse event  
BMI  body mass index  
AESI  adverse event of special interest  
CDISC  Clinical Data Interchange Standards Consortium  
CFR  Code of Federal Regulations  
CSR  clinical study report  
CRO  contract research organization  
ECG  electrocardiogram  
eCRF  electronic case report form  
FAS full analysis set  
ICH International Council for Harmonisation  
IMP investigational medicinal product  
IV intravenous(ly)  
LLOQ  lower limit of quantification  
MedDRA  Medical Dictionary for Regulatory Activities  
MRT  mean residence time  
NPH  neutral protamine Hagedorn  
PD pharmacodynamic(s)  
PK pharmacokinetic(s)  
PPS per protocol set  
PR PR interval; ie, the measure of the time between the start of the p wave and 
the end of the r wave in the heart’s electrical cycle  
QRS  QRS interval; ie, the measure of the time between the start of the q wave and 
the end of the s wave in the heart’s electrical cycle  
QT  QT interval; ie, the measure of the time between the start of the q wave and 
the end of the t wave in the heart’s electrical cycle  
QTc corrected QT interval  
QTcF  QTc according to Fridericia’s formula  

 
Zealand Pharma A/S   Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)  16 August 2019  
 
TMP -SOP -0202 -001-03_SAP Template  Page 6/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  SAE  serious adverse event  
T1DM  type 1 diabetes mellitus  
TLF tables, listings, and figures  
  
Plasma concentrations of dasiglucagon/GlucaGen  
AUC 0-30min Area under the plasma concentration versus time curve from 0  to 30 minutes 
post-dose 
AUC 0-300min  Area under the plasma concentration versus time curve from 0  to 300 
minutes post -dose 
AUC 0-inf Area under the plasma concentration versus time curve from 0 to infinitly 
post-dose 
Cmax Maximum of all valid plasma concentration measurements from 0 to 300 
minutes post -dose 
tmax Time to maximum of plasma concentration measurements  
λz Terminal elimination rate constant  
t½ Terminal plasma elimination half -life 
CL/f  Total body clearance  
Vz/f Volume of distribution  
MRT  Mean residence time  
  
Plasma glucose concentrations  
AUE 0-30min Plasma glucose response as area under the effect curve above baseline from 
time 0 to 30 minutes  
 

 
Zealand Pharma A/S   Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)  16 August 2019  
 
TMP -SOP -0202 -001-03_SAP Template  Page 7/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  1. INTRODUCTION  
This document outlines the statistical methods to be implemented during the analyses of data 
collected within the scope of Zealand Pharma A/S protocol ZP4207 -1708 6. The purpose of this 
plan is to provide specific guidelines from which the statistical analy ses will proceed. Any 
deviations from this plan  will be documented in the clinical study report (CSR).  
 
2. STUDY DOCUMENTS  
The following study documents are used for the preparation of the statistical analysis plan ( SAP): 
 Protocol version 3.0, dated 08 Januar y 2019  
 Annotated electronic case report form (e CRF ) version 1.0, 11 September 2018  
 Data management plan version 1.0, 23 August 2018  
 
3. STUDY  OBJECTIVES  
3.1 Primary Objective  
To demonstrate that dasiglucagon is superior to placebo following a single injection of 0.6 mg of 
dasiglucagon in treating hypoglycemia in children with type I diabetes mellitus ( T1DM ) 
3.2 Secondary Objective  
 To confirm that a single dose of dasiglucagon [ 0.6 mg] is comparable to a single dose of 
GlucaGen® [1 mg/mL] in treating hypoglycemia in children with T1DM (in accordance 
with the label, children below 25 kg body weight will be administered 0.5 mg 
GlucaGen®)  
 To assess safety profile of dasiglucagon in children with T1DM  
 To assess pharmacokinetic ( PK) profile of dasiglucagon in children with T1DM  
4. STUDY DESIGN AND  PLAN  
This is a phase 3, randomized, double -blind, placebo - and active -controlled, parallel -arm trial 
designed to assess efficacy, safety and PK of dasiglucagon v ersus placebo and v ersus  
GlucaGen ® in children with T1DM. At the time of protocol finalisation it was anticipated that it 
will be conducted at 2 -3 centers  in Europe and 1 -2 centers  in the US A. 
 
The trial will include the following periods (as illustrated in Figure 4-1). 
 A screening period from Day  -30 to Day  -3 

 
Zealand Pharma A/S   Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)  16 August 2019  
 
TMP -SOP -0202 -001-03_SAP Template  Page 8/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019   A treatment period, from Day  0 to Day 1 (day of randomization and single dosing with 
trial product). Unblinded trial personnel will do the handling, preparation and 
administration of trial product. All trial assessments will be done by blinded trial 
personnel  
 A follow -up visit at Day  28 (the end -of-trial visit)  
 
Figure 4-1 Overview of the Trial Design  
 
Abbreviation: PK=pharmacokinetic  
The schedule of assessments ( refer to the study protocol ) gives a n overview of the trial 
procedures. Patients should attend  all visits on the designated day or as close to it as possible.  
 
5. DETERMINATION OF SAMPLE SIZE  
The primary comparison is between the dasiglucagon and placebo treatment arms. From phase 2 
results, t he median time to an increase of 20 mg/dL of the 0.6 mg dose was approximately 10 
minutes. For placebo -treated patients, the median time to recovery is assumed to be more than 50 
minutes. Assuming an exponential time -to-recovery distribution with median ti mes of 10 and 50 
minutes, a 2 -sided log -rank test will be able to detect a difference between dasiglucagon 0.6 mg 


 
Zealand Pharma A/S   Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)  16 August 2019  
 
TMP -SOP -0202 -001-03_SAP Template  Page 9/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  and placebo with 90% power with a follow -up time of 45 minutes at a 5% significance level with 
20 patients randomized to the dasiglucagon arm and 10 patients to placebo.  
GlucaGen® is included as a reference to compare the responses and AE profile to dasiglucagon 
with those to a marketed product. It is expected that 10 patients in the GlucaGen® group will 
suffice for the comparison.  
6. GENERAL ANALY SIS CONSIDERATIONS  
The statistical analyses will be reported using summary tables, listings , and figures (TLFs) . The 
International Council for  Harmoni sation ( ICH) numbering convention will be used for all TLFs . 
Unle ss otherwise noted, all statistical testing will be 2-sided and will be performed at the 0.05 
significance level. Tests will be declared statistically significant if the calculated P value is 
≤0.05 .  
 
All data obtained in this trial and documented in the eCRFs will be listed and summarized with 
statistics or frequency tables as appropriate. In case of termination of the trial, all data collected 
up to that time point will be included into the analysis.  
 
Continuous variables will be summarized with means, s tandard deviations, medians, minimums, 
and maximums  and valid cases . Other summaries ( eg, quartiles, 5%, 95% intervals) may be used 
as appropriate.  For  PK parameters except Tmax, geometric mean and geometric %  CV will be 
calculated.  
 
Categorical variables will be summarized by counts and by percentage of patients in 
corresponding categories. Percentages for missing values are omitted and do not account for the 
percent calculation of other categories. Percentages are routinely based on the total ca tegory 
count excluding the missing category if not otherwise mentioned. Percentages showing a rate 
relative to the total number of patient s in this group are given in special tables ( eg, adverse event 
[AE] tables). Footnotes will specify the percent basis  in those cases . 
 
All summary tables will be presented by treatment group  if possible and  also include a total 
summary column . 
 
Individual patient data obtained from the  eCRFs, external vendors , and any derived data will be 
presented by patient in data list ings.  
 
The analyses described in this plan are considered a priori, in tha t they have been defined prior to 
breaking the blind.  
 
Any analyses performed subsequent to breaking the blind will be considered post  hoc and 
exploratory. Post  hoc analyses will be labeled as such on the output and identified in the CSR.  
 
All analyses and tabulations will be performed using SAS software Version 9.4 or higher. 
Pharmacokinetic and pharmacodynamic (PD) analyses will be performed using Phoenix® 

 
Zealand Pharma A/S   Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)  16 August 2019  
 
TMP -SOP -0202 -001-03_SAP Template  Page 10/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  WinN onlin Version 6.4 or higher. Tables , listings , and figures  will be presented in ASCII or 
RTF format.  
 
The process for SAS program validation and quality control (QC) for programs and outputs is 
documented in the Synteract working instruction “SAS programming quality control .” 
Study -specific QC requirements can be found in Appendix  B: SAS Programming QC 
Requirements . 
 
7. NOTATION OF TREATMEN T GROUP S AND VISITS  
Notation of treatment groups  
 
The following notation of  treatment groups  will be used throughout the report:  
Full notation (as used in the study protocol)  Notation as used throughout all 
tables, listings , and figures  
Dasiglucagon, liquid formulation, 1 mg/mL, 0.6 mL  dasiglucagon  
1 mg lyophilized powder for reconstitution (GlucaGen®, 
Novo Nordisk)  GlucaGen  
Placebo treatment: Placebo, liquid formulation, 0.6 mL  Placebo  
 
Visit terminology  
 
Visit  Notation as used throughout all tables, 
listings , and figures  
V1 Screening  Screening  
V2 Dosing  Dosing  
V3 Follow up  Follow up  
 
8. ANALYSIS SETS  
For the statistical analysis, the randomized patients will be divided up into the following datasets . 
The following definitions are applicable:  
 
Safety analysis set  All patients who were randomized and received at least 1 dose 
of trial product . Treatment assignment will be based on the 
treatment actually received.   
Full analysis set  (FAS)  All patients of the safety analysis set . Treatment assignment 
will be based on the randomized treatment. Assignment to the 
stratification factor injection site will be based on the planned 

 
Zealand Pharma A/S   Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)  16 August 2019  
 
TMP -SOP -0202 -001-03_SAP Template  Page 11/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  and not the actual used injection site . 
Per protocol set (PPS)  All patients of the FAS for whom no releva nt protocol 
deviations were documented . Treatment assignment will be 
based on the randomized treatment. Assignment to the 
stratification factor injection site will be based on the planned 
and not the actual used injection site. 
 
The analysis of the primar y endpoint will be based on the FAS. A secondary analysis of the 
primary endpoint will be based on the PPS. Safety analysis will be based on the safety analysis 
set. 
The decision whether a protocol deviation is relevant or not for the exclusion of patients  from the 
PPS will be made case -by-case in a data review meeting  before breaking the blind . 
  
9. STUDY POPULATION  
9.1 Patient Disposition  
Patient disposition information will be summarized for all patients by treatment group. 
Summaries will include: the number of  patients screened, the number of randomized patients , 
and the number of patients in each analysis set. 
 
The number of patients who completed or discontinued the study will be tabulated by treatment. 
In addition, for patients who discontinued, the primary reason will be tabulated by treatment 
group.  
 
Patient numbers  and percentages in each country and patient numbers  and percentages in each 
country and center  will be presented by treatment group.  
In additon, the number of patient numbers and percentages of US versus non -US countries will 
be tabulated by treatment group.  
 
9.2 Protocol Deviations  
A listing of all protocol deviations  including the deviation designation  (relevant/non -relevant ), 
category, and indication of whether the deviation le d to an exclusion of  a patient from the PP S 
will be presented in a data listing.    
 
9.3 Eligibility  
A listing of patient s not fulfilling  any eligibility criteria will be created.  This listing will consider 
and differentiate eligibility criteria at screening as well as the r e- check of dosing day exclusion 
criteri a. 

 
Zealand Pharma A/S   Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)  16 August 2019  
 
TMP -SOP -0202 -001-03_SAP Template  Page 12/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  9.4 Demographic and Baseline Characteristics  
Demographic variables include: age, age group (6 -11 years, 12 -17 years), sex, childbearing 
potential, ethnicity, and race.  
 
Summary statistics will be presented for the above -mentioned variables by treatment group.  
 
Other baseline characteristics include: diabetes history, medical history  and body measurements 
(height, weight, BMI).   
BMI will be additionally classified into the following categories : 
<25 
 25-<30 
30-<35 
>=35  
A summary table for BMI by BMI class and country will be created.  In addition, this table will 
show BMI classes of US versus non -US countries.  
 
Diabetes history  
Time since diagnosis of diabetes 1 (based on date of informed consent and start date of diabetes 
1) (years) will be tabulated with descriptive statistics by treatment group. If the day is not 
available, the calculation of duration will be based on month and year only, setting the start day 
to 1. In case only the year is available, the start day will be 1 and the start month will be January.  
 
Body measurements  
 
Separate descriptive statistics will be presented for body measurements (height, weight, BMI)  by 
treatment group.  
 
Medical history  
The v erbatim term of the medical history condition/event  will be coded using Medical  
Dictionary for Regulatory Activities (MedDRA ), version 22.0.  
A summary will be prepared by treatment group. The summary  will show the system organ class 
and preferred terms ordered by descending order of incidence of system organ class  and 
preferred term within each system organ class.  
 
Demographic and baseline characteristics will be summarized for the safety analysis set and 
FAS. If the safety analysis set and FAS are identical, then it will be sufficient to state this in the 
table o utput section.  
 
Other information documented at screening  
Analyses of other screening or baseline variables  as listed below , which are documented  at 
screening/baseline and /or have further evaluations after the screening/baseline visit will be 
described in subsequent sections.  
 

 
Zealand Pharma A/S   Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)  16 August 2019  
 
TMP -SOP -0202 -001-03_SAP Template  Page 13/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019   Physical examination   
 Vital signs  
 12-lead electrocardiogram (12 -lead ECG)   
 Central safety laboratory (hematology, biochemistry, coagulation, urinalysis)  
 Antibody serum sample for immunogenicity measurements  
9.5 Concomitant Medications  and Current Diabetes Treatment   
Concomitant medication  and current diabetes treatment  verbatim terms in the  eCRFs will be 
mapped to Anatomical/Therapeutic/Chemical (ATC) class  and preferred  names using the 
WHO Drug Global (version  March  2018 ). 
 
All concomitant  medications  and current diabetes treatment  will be listed as documented in the 
eCRF. In this listing the WHODrug coding including the drug name as documented in the eCRF, 
the drug name used for the coding, the preferred term, the ATC  code and the ATC  term will be 
included as well.  
Coding will be done using ATC level 4, which will be presented in  the listings.  
 
Concomitant medications  and current diabetes treatment  will be summarized for each treatment 
by WHO ATC class (level 2) and preferred name. These summaries will present the number and 
percentage of patients using each medication. Patients may have more than 1 medication per 
ATC class and preferred name. At each level of patient summarization, a patient is counted once 
if he/she reported 1 or more me dications at that level. Each summary will be ordered by 
descending order of incidence of ATC class and preferred name within each ATC class.  
 
In case the centers also captured true p rior medications , this will only be listed  and a flag will be  
included in  the raw data listing denoting whether the medication is prior or concomitant . 
 
The distinction between previous and concomitant med ication will be done as follows:  
 Prior medication is all medication which stopped  before the first investigational 
medicinal  product ( IMP) administration within the trial context , independent from st art 
date.  
 Concomitant medication is all medication that started prior to the first IMP administration 
and is still ongoing  or stopped at date of first study drug intake - or medica tion that 
started at/after the date of the first drug intake.  
 If the start or stop date is incomplete and the allocation to previous or concomitant is not 
clear, the medication will be considered to be concomitant.  
10. EFFICACY ANALYSES  
The primary efficacy an alysis will be based on the FAS. Analogous supportive sensitivity 
analyses will be conducted in the PPS, but without inference intent . 

 
Zealand Pharma A/S   Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)  16 August 2019  
 
TMP -SOP -0202 -001-03_SAP Template  Page 14/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  10.1 Efficacy Variables  
The primary  efficacy variable is:  
 
 Time to plasma glucose recovery. Plasma glucose recovery is defined  as first increase in 
plasma glucose of ≥20 mg/dL (1.1 mmol/L) from baseline during the hypoglycemic 
clamp procedure1 without administration of rescue intravenous (IV) glucose . Time to 
recovery is considered only within the first 45 minutes from baseline.  
In this trial, plasma glucose for pharmacodynamics is reported with the unit ‘mmol/l’. For 
consistency, these results are converted into the unit ‘mg/dl’ by using the conversion 
factor 0.0555 (i.e. Glucose [mg/dl]=Glucose [mmol/l] /0.055 5). 
 
Secondary  efficacy variables include the following:  
 
 Plasma glucose recovery  within 30 minutes, within 20 minutes, within 15 minutes, and 
within 10 minutes after study drug in jection without administration of rescue IV glucose . 
 Plasma glucose changes from baseline  at 30 minutes, at 20 minutes, at 15 minutes, and at 
10 minutes after study drug injection  or at the time of rescue  IV glucose . 
10.2 Baseline Values  
Unless otherwise noted, baseline is defined as the last non-missing value recorded prior to the 
first dose of stu dy drug . Unscheduled visits will be used in the determination of baseline values, 
when applicable.  
10.3 Adjustments for Covariates  
The model for the primary efficacy will include adjustments for the following covariates:  
 Age group: 6-11 years, 12 -17 years  
 Injection site: abdomen/thigh  
10.4 Handling of Dropouts or Missing Data  
Only non-missing  cases will be analyzed, ie, no imputation technique like last observation 
carried forward will be applied.  Summaries will be based on observed data only.  
10.5 Interim Analys is and Data Monitoring  
There are no planned interim analyses for this study.  
                                                 
1 For simplification the addition ‘ during the hypoglycemic clamp procedure ’ will be omitted further on.  

 
Zealand Pharma A/S   Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)  16 August 2019  
 
TMP -SOP -0202 -001-03_SAP Template  Page 15/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  10.6 Examination of Subgroups  
No subgroup analysis is planned.  
10.7 Multiple Comparison/ Multiplicity  
For the confirmatory analyses  of the primary and secondary  endpoints , patients treated wit h 
either  dasiglucagon 0.6 mg and or placebo will be compared. A hierarchical procedure will be 
applied for the control of multiplicity. The primary and secondary endpoints will be evaluated on 
the FAS.  
 
For the confirmatory analyses, the following a prior i-defined hierarchical inferential test order 
will be applied for the control of the type 1 error rate across the planned multiple comparisons. 
The primary endpoint and secondary  endpoints will be inferentially evaluated within the FAS in 
the following ord er, where inference will proceed at the 2-sided 0.05 criterion significance level 
until the first failure to reject the null hypothesis for a dasiglucagon versus placebo comparison:  
 Primary:  Time to plasma glucose recovery  
 Secondary 1 -4: Plasma glucose re covery within 30 minutes, within 20 minutes, within 15 
minutes, and within 10 minutes after study drug injection without administration of 
rescue IV glucose.  
 Secondary 5 -8:  Plasma glucose changes from baseline at 30 minutes, at 20 minutes, at 15 
minutes, and at 10 minutes after study drug injection or at the time of rescue.  
 
The GlucaGen ® versus placebo comparisons will not be included in the inferential testing 
hierarchy, since the efficacy of GlucaGen® is previously established, and these comparisons are 
intended to support the validity of the study for the dasiglucagon versus placebo comparisons.  
Moreover, the comparison of dasiglucagon versus GlucaGen ® is not part of this hierarchial 
testing procedure . 
 
10.8 Multicenter Studies  
This is a multicenter study , having approximately  5 centers participating in the study . The factor 
center will not be accounted for in the primary statistical analysis model.  
 
 
11. METHODS OF EFFICACY ANALYSIS  
11.1 Primary Efficacy Analyses  
The primary endpoint , time to plasma glucose recovery,  will be summarized using Kaplan -Meier 
estimates  per treatment group .  

 
Zealand Pharma A/S   Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)  16 August 2019  
 
TMP -SOP -0202 -001-03_SAP Template  Page 16/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  The actual  time points at 0, 4, 6, 8, 10, 12, 15, 17, 20, 30, 45 and 60 minutes will be used in the 
analyses.  
Kaplan -Meier plots will be created showing the the estimated survival function for each 
treatment in one plot.  
In the primary analysis, recovery cannot be achieved in those subjects where rescue IV glucose 
treatment is administered. Those subjects who rece ive rescue IV glucose will be censored ( and 
set to ‘not recovere d’) at 45 minutes after dosing.  
For patients who did not recover within 45 minutes after dosing, time to recovery is censored at 
45 minutes. 
 
The stratified log -rank test will be applied to co mpare the dasiglucagon 0.6  mg treatment group 
to the placebo group. The same method will be applied to compare dasiglucagon 0.6  mg with 
GlucaGen®, but not considered for the confirmatory hierarchial testing procedure.  
 
In order to facilitate this, SAS proc edure proc lifetest is used. The following code will be used, 
but minor variations can be applied during programming:  
 
proc lifetest data=xx  plots=survival(atrisk=0  10 15 20 30 45);  
   time aval * Status(0);  
   strata age site/ group= treat test=logrank diff=all;  
   run;  
 
where “aval” is the time to plasma recovery, and “status” is a censor variable for patients who 
receive IV glucose. Age group and injection site are the stratification variables and “treat” the 
planned treatment assignment.  
 
The unstratified result of the log -rank test can be obtained from the following code:  
proc lifetest data=xx  plots=survival(atrisk=0  10 15 20 30 45);  
   time aval * Status(0);  
   strata treat / test=logrank diff=all;  
   run; 
In sensitivity analyses, the time to plasma glucose recovery will be analyzed  
1) without censoring for those subjects who require rescue IV glucose before 45 minutes and  
2) with censoring at the time of administration of rescue IV glucose before 45 m inutes.  
As a supportive analysis to the stratified log -rank test for the time to plasma glucose recovery, 
dasiglucagon will be compared to placebo using a Wilcoxon test stratified by age group and 
injection site.  
To graphically describe recovery in time, a  histogram showing the proportion of patients that 
recovered at each time interval will be created, one for each treatment group.  
The primary endpoint will additionally be analyzed using a discrete -time Cox proportional 
hazards (CPH) time to event statisti cal model, if the hazards by treatment group can be assumed 

 
Zealand Pharma A/S   Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)  16 August 2019  
 
TMP -SOP -0202 -001-03_SAP Template  Page 17/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  proportional using a graphical comparison of log -minus -log survival curves and no more than 
two-thirds of the recovery times are censored in each treatment group. The CPH model will be 
used for descriptive purposes , with treatment group , age group  and injection site modeled  as 
categorical effects, and baseline plasma glucose modelled as a continuous covariate. The 
treatment group hazard ratios of active versus placebo, will be estimated together wi th the 95% 
confidence intervals, and pairwise treatment group inferences (dasiglucagon vs placebo, 
GlucaGen vs placebo , dasiglucagon vs GlucaGen ) will be evaluated using least-square mean and 
standard deviation estimates . 
Due to the discrete  nature of blood sampling  in time,  and the fact that there must be a true, but 
unmeasured,  ordering of the recovery times , the method using the “exact discrete” partial 
likelihood for tied failure  times  will be applied.  In SAS, this is implemented in the phreg  
proced ure with the option ties=discrete . The influence of age and injection site on time to 
recovery will also be evaluated in the proportional hazards model by a ‘type 3’ test in the phreg  
procedure.  
 
In addition, separate CPH models will be calculated to evalu ate homogenicity for the following 
factors:  
Sex, BMI cl ass, ethnicity, race, US/non -US. 
 
These additonal h omogenicity models  are only presented for the primary efficacy analysis, but 
not for subseqent varia nts of that analysis.  
 
To obtain an estimate of these true, but unassessed, patient recovery times, a linear interpolation 
(between the two time points before and after recovery is observed) will be carried out to 
estimate the patients’ actual time of recovery . These derived rec overy times will be described 
and analysed in the same manner as for the discrete times above.  
 
Let t 1 and t 2 be the 2 time points before and after recovery is observed and y 1 and y 2 be the 
corresponding changes from baseline in glucose concentrations, whe re y 1 is below 20 mg/dL and 
y2 is greater than 20  mg/dL.  
 
The interpolated time point t ext is calculated then as:  
 
) () ( * ) 20(
1 21 2 1
1y yt t yt text  
 
 
This linear interpolation is only used as a supportive analysis to  the primary analysis model using 
proc lifetest.  
In this  statistical model, ties=exact will be used.  

 
Zealand Pharma A/S   Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)  16 August 2019  
 
TMP -SOP -0202 -001-03_SAP Template  Page 18/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  11.2 Secondary Efficacy Analyses  
The secondary  efficacy endpoints are plasma glucose recovery within  10, 15, 20 and 30  minutes 
after trial product injection, ie, achieving a ≥ 20 mg/dL increase in plasma glucos e from baseline 
at 0 to 10, 15, 20 , and 30  minutes.  
Actual  timepoints of sampling will be used for this calculation.  
If a patient  has received an IV glucose treatment before recovery, the patient  is set to  “not 
recovered ” in the analysis of the 4 endpoints, corresponding to censoring in the time -to-recovery 
analysis for the primary endpoint. The 10-, 15-, 20-, and 30 -minute recovery rate s of 
dasiglucagon and Placebo will be compared by a Cochran -Mantel -Haen szel test stratified by age 
group and inj ection site. The treatment responder rates with the 95% confidence intervals will be 
presented for the 10-, 15-, 20-, and 30 -minute endpoint s. 
 
If due to small or zero cell counts the Cochran -Mantel -Haen szel test fails, non -stratified Fisher 
exact tests wi ll be applied instead.  
 
 
Plasma glucose changes from baseline at 10, 15, 20 , and 30  minutes after trial product injection 
will be analyzed in an analysis of variance  with factors treatment (3 levels) , age group (2 levels) , 
and injection site (2 levels) for  each endpoint. If the rescue IV glucose was administered before 
10, 15, 20 , or 30  minutes, respectively, the patient ’s plasma glucose changes from baseline will 
be determined from the value at the time of rescue IV glucose administration.  
The change from  baseline is calculated using the nominal sampling time.  
 
Least -square mean a djusted treatment means will be presented with their 95% confidence 
intervals  including the 95% confidence intervals for the treatment difference . The analysis of 
variance  at each  of the 4 time points will also be used to tes t the difference of dasiglucagon and 
Placebo  adjusted for age group and injection site.  
 
  
12. PHARMACOKINETIC ANAL YSES  
Plasma dasiglucagon and glucagon concentrations will be described and the following 
parameters are calculated and summarized with descriptive statistics : 
 
PK parameter  PK parameter 
abbreviation  Calculation  
Area under the plasma 
dasiglucagon or GlucaGen® 
concentration versus time curve 
from 0  to 30  minutes post -dose  AUC 0-30min Linear trapezoidal rule for the ascending 
part of the concentration -time curve, 
logarithmic trapezoidal rule for the 
descending part.  
Area under the plasma 
dasiglucagon or GlucaGen® 
concentration versus time curve AUC 0-300min  Linear trapezoidal rule for the ascending 
part of the concentration -time curve, 
logarithmic trapezoidal rule for the 

 
Zealand Pharma A/S   Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)  16 August 2019  
 
TMP -SOP -0202 -001-03_SAP Template  Page 19/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  PK parameter  PK parameter 
abbreviation  Calculation  
from 0 to 300  minutes post -
dose  descending part.  
Area under the plasma 
dasiglucagon or Gluca Gen® 
concentration versus time curve 
from 0 to infinitely post -dose  AUC 0-inf (AUClast + Clast obs)/ λz, where Clast obs is the 
concentration corresponding to Tlast  (time 
of last measurable (positive) concentration ). 
Maximum of all valid plasma 
dasiglucagon  or GlucaGen® 
concentration measurements 
from 0  to 300  minutes post -
dose  Cmax Taken directly from analytical data , selected 
from individual concentration data . The 
time when the first occurrence of Cmax is 
taken as Tmax.  
Time to maximum of plasma 
dasiglucagon or GlucaGen® 
concentration measurements  tmax Taken directly from analytical data , selected 
from individual concentration data  
Terminal elimination rate 
constant of plasma 
dasiglucagon or GlucaGen®  λz Calculated by linear regression of the 
terminal linear portion of the log 
concentration vs. time curve. At least 3 
concentrations in the terminal elimination 
phase will be required to calculate λz.  
Terminal plasma elimination 
half-life of dasiglucagon or 
GlucaGen®  t½ Ln(2)/  λz 
Total body cle arance of plasma 
dasiglucagon or GlucaGen®  CL/f  Dose / AUC 0-inf 
Volume of distribution of 
plasma dasiglucagon or 
GlucaGen®  Vz/f Dose/ ( λz * AUC 0-inf) or CL/f/  λz 
Mean residence time of plasma 
dasiglucagon or GlucaGen®  MRT  AUMCinf/  AUC 0-inf where AUMCinf is the 
area under the first moment curve as 
estimated by WinNonlin.  
 
 
The PK metrics as listed above will be obtained by non -compartmental analysis using the 
computer programs Phoenix® WinNon lin Version 6.4.  
 
12.1 Data Handling  
Plasma dasiglucagon  and GlucaGen® are determined at pre-dose, and at 10, 20, 30, 40, 60, 90, 
140, 220, and 300 minutes after dosing. The actual time of blood sampling should not deviate 
from the nominal time by more than ±1 min ute between t=5 min utes and t=90 min utes, ±5 

 
Zealand Pharma A/S   Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)  16 August 2019  
 
TMP -SOP -0202 -001-03_SAP Template  Page 20/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  minutes between t =140 min utes and t=240 min utes. Pre-dose is defined as within 2 minutes prior 
to dosing) . 
 
Summary tables and figures for plasma concentrations:  
 
i.) For all pre -dose samples, the sampling time will be set to zero.  
ii.) For post -dose samples, the planned sampling time will be used in summary tables 
and the actual sampling times will be used for all figures of individual 
concentrations .  
iii.) All concentration values < lower limit of quantification ( LLOQ ) will be set to zero.  
iv.) Missing post -dose values will not be replaced.  
 
Determination of PK metrics:  
 
i.) For all pre -dose samples, the sampling time will be set to zero.  
ii.) For post -dose samples, the actual sampling time will be used.  
iii.) All pre -dose concentration values will be set to zero.  
iv.) Post-dose c oncentration values < LLOQ before tmax will be set to zero if there are 
no further concentrations > LLOQ at later time points.  
v.) Post-dose concentration values < LLOQ before t max will be set to the lower limit of 
quantitation if there are further concentrati ons > LLOQ at later time points.  
vi.) Post-dose concentration values < LLOQ after t max will be ignored if there are no 
further concentrations > LLOQ at later time points.  
vii.) Post-dose concentration values < LLOQ after t max will be ignored if there are 
further concentrations > LLOQ at later time points.  
viii.) Missing post -dose values will not be replaced.  
 
PK metrics will be determined by Synteract . Plasma  concentration data will be transferred from 
an external laboratory (York Bioanalytical Solutions (YBS), MLM labor atories)  to Synter act as 
detailed in separate data transfer specifications.  
12.2 Presentation of Plasma Concentrations and PK metrics  
Individual plasma concentration results :  
A raw data listing will be provided displaying the concentration as reported, the result used in 
summary tables and mean time -concentration curves , and the change from pre -dose result.  
Results will be displayed using 3 significant digits.  
 
Summary statistics of plasma concentration table:   
Summary statistics  of the plasma  concentration by treatment group and time point will be 
presented.  In addition, the change from pre -dose will be summari zed. Results will be displayed 
using 3 significant digits.  
 
PK metrics:   

 
Zealand Pharma A/S   Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)  16 August 2019  
 
TMP -SOP -0202 -001-03_SAP Template  Page 21/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  Summary statistics of PK metrics will be presented by treatment  group . Results will be displayed 
using 3 significant digits.  
 
Figures:  
1. Mean concentrations versus nominal time by treatment group using the original 
(untransformed) scale  of concentrations . The curves of each treatment group will be put 
into 1 graph, having an ov erlay plot in the end with 2 curves  for each treatment group . 
(Samples from patients receiving placebo will not be analyzed by the laboratories that 
will be analyzing for dasiglucagon and GlucaGen®.)  
2. Mean concentrations versus nominal time by treatment group using the log scale  of 
concentrations . The curves of each treatment group will be put into 1 graph, having an 
overlay plot in the end with 2 curves  for each treatment group . (Samples from patients 
receiving placebo will not be analy zed by the laboratories that will be analyzing for 
dasiglucagon and GlucaGen®.)  
3. Individual dasiglucagon and glucagon concentrations versus nominal time curves using 
the original concentration scale  overlaying all patients per treatment group  will be 
prepared .  
 
13. PHARMACODYNAMIC ENDP OINTS  
Plasma glucose is determined at pre-dose and at 4, 6, 8, 10, 12, 15, 17, 20, 30 , and 45 minutes 
(and as well at 60 minutes if the patient´s body weight is ≥21 kg) after dosing. The actual time of 
blood sampling should not deviate from the nominal time by more than ±30 seconds until the 
20-minute collection time point, and by more than ±1 minute for the subsequent collection time 
points. Pre -dose is defined as within 2 minutes prior to dosing  
 
The pharmacodynamic  endpoin t is the p lasma glucose response as area under the effect curve 
above baseline from time 0 to  30 minutes (AUE 0-30min). AUE 0-30min will be calculated using SAS 
software.  
 
Individual plasma glucose concentration results :  
A raw data listing will be provided displaying the concentration as reported, the result used in 
summary tables and mean time -concentration curves and the change from pre -dose result.   
 
Summary statistics of plasma glucose concentration table:   
Summary statistics  of the plasma  glucose concentration by treatment group and time point will 
be presented.  In addition, the change from pre -dose will be summari zed.  
 
Pharmacodynamic  metrics:   
Summary statistics of pharmacodynamic metrics will be presented by treatment  group .  
 
Figures:  

 
Zealand Pharma A/S   Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)  16 August 2019  
 
TMP -SOP -0202 -001-03_SAP Template  Page 22/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  1. Mean glucose  concentrations versus nominal time by treatment group using the original 
(untransformed) scale  of concentrations . The curves of each treatment group will be put 
into 1 graph, having an overlay plot in the end with 2 curves for each treatment group.   
2. Individual glucose  concentrations versus nominal time curves  using the original 
concentration scale overlaying all patients per treatment group  will be prepared.  
 
14. SAFETY ANALYSES  
All safety analyses will be based on the safety  set. 
14.1 Extent of  Exposure  
14.1.1  Insulin administration prior to the hypoglycemia induction procedure  
All details with regard to insulin administration prior to the hypoglycemia induction procedure  
will be listed.  This includes whether the patient  used multiple daily injections, long -acting 
insulin, s hort-acting insulin ( except insulin glulisine [Apidra®]), insulin NPH , or insulin glulisine 
(Apidra®) or an insulin pump . 
 
A summary table will be prepared showing the number (percentage) of patients who used any of 
the following:  
 Multiple dai ly injections  
 Insulin NPH   
 Insulin pump  
 Insulin glulisine (Apidra®) 
14.1.2  Hypoglycemia induction procedure  
All details with regard to the h ypoglycemia induction procedure  will be listed.  
A summary table will be prepared showing the number (percentage) of patient s where the 
hypoglycemia induction procedure  was performed , the t otal amount of insulin administered to 
induce hypoglycemia  and the total amount of glucose administered during the induction 
procedure . 
14.1.3  Trial medication administration  
All details with  regard to the trial medication administration will be listed.  
A summary table will be prepared showing the number (percentage) of patient s where the trial 
medication was administered.  

 
Zealand Pharma A/S   Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)  16 August 2019  
 
TMP -SOP -0202 -001-03_SAP Template  Page 23/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  14.1.4  Post-treatment rescue glucose  infusion  
All details with regard to the p ost-treatment rescue glucose  infusion  will be listed.  
A summary table will be prepared showing the number (percentage) of patient s where glucose  
was given as rescue medication.  
 
The t ime to first IV glucose infusion, after IMP administration ( IV glucose in fusion prior to IMP 
administration should not be included, as it is part of hypoglycemic clamp procedure)  will be 
described with descriptive statistics. No statistical tests will be performed.  
 
Time to first IV glucose infusion  [min utes] is calculated as :  
 
Time of start of first glucose admin istration – Time of administration of study medication . 
No censoring is done in case no IV glucose infusion is given, ie, the descriptive statistics only 
show data when a n infusion was given.  
14.2 Local Tolerability  
Local tolerability at the injection site is assessed  at 30, 120, and 300 minutes after dosing  and at 
Follow -up. 
The following symptoms are assessed:  
 Spontan eous pain  
 Pain on palpation  
 Itching  
 Redness  
 Edema  
 Induration/Infiltration  
 Other types of reaction  
 
All details of local tolerability assessment are listed.  Any local reaction will also be reported as 
AE. 
 
 
The analysis of local tolerability will include a summary table  displaying counts and percentages 
of patient s experiencing local symptoms by time point, symp tom and grade (intensity) .  
 
The category “other types of reactions ” will not be included in this summary due to lack of a 
distinct unique reaction term.  
 

 
Zealand Pharma A/S   Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)  16 August 2019  
 
TMP -SOP -0202 -001-03_SAP Template  Page 24/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  14.3 Adverse Events  
All AE summaries except for 1 overview table will be restricted to treatment -emerg ent AEs 
(TEAE s), which are defined as those AEs that occurred after dosing and those existing AEs that 
worsened during the study . A manual check is done for AEs that start prior dosing and continue 
after dosing whether the intensity of the AE worsened.  
 
If it cannot be determined whether the AE is treatment emergent due to a partial onset date , then 
it will be counted as such  unless the end date  is before dosing . Verbatim terms in the eCRFs  will 
be mapped to preferred terms and system organ cla sses using the MedDRA , version 21.0 or 
higher .  
 
Each AE summary will be displayed by treatment group.  
 
Causal relationship:  Causal relationship between the occurrence of an AE and the 
administration of the study drug is assessed by the investigator according to cla ssification 
scheme  0=not related , 1=unlikely related , 2=possibly related  and 3= probably related . Probable  
and possible relationship are subsumed under the category related.  All AEs must have a causal 
relationship assigned.  In case of a missing relationship, a query will be raised in order to obtain 
causality assessment . In case no c larification of relationship via query is possible the missing 
relationship will be set to related for the analysis.  
Severity : Severity grading will differ between 1=mild, 2=moderate and 3=severe. For AEs 
having a missing severity, the severity will not be imputed and kept as missing.  
14.3.1  Summary of adverse events  
An overview AE summary table will be prepared showing the number and p ercentage of patient s 
with at least 1 event and the total number of events for the following selections : 
1. AEs during screening  
2. TEAEs  
3. TEAEs, which are adverse events of special interest  (AESIs)  
4. TEAEs, which are an other important event  
5. TEAEs, which are inje ction site reactions  based on investigator assessment in CRF  
6. Injection site reactions based on special search category provided by Zealand  
7. Study drug -related TEAEs  
8. Serious TEAEs  (SAEs)  
9. Study drug -related serious TEAEs (serious study drug -related TEAEs ) 
10. Deaths  
The summary table is based on the number of AE verbatim  terms.  

 
Zealand Pharma A/S   Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)  16 August 2019  
 
TMP -SOP -0202 -001-03_SAP Template  Page 25/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  14.3.2  Adverse event tables  
In addition, frequency tables will be prepared by MedDRA terms ( system organ class, preferred 
term) showing the following:  
1. All TEAEs  
2. TEAEs, which are AESIs  
3. TEAEs, which are an other important event  
4. TEAEs, which are injection site reactions  based on i nvestigator assessment in CRF  
5. Study -drug related TEAEs  
6. TEAEs by causal relationship to study drug  
7. TEAEs by severity  
8. Serious TEAEs  (SAEs)  
9. Special search category TEAEs  
The analysis of AEs will include summary tables displaying counts and percentages of patient s 
experiencing AEs by system organ class and preferred term. If a patient  has more than 1 AE 
which codes to the same preferred term, the patient  will be counted only once for that preferred 
term. The total number of events documented per system order class and preferred te rm will also 
be displayed.  Summaries will be ordered by descending order of incidence of system organ class 
and preferred term within each system org an class  based on the frequency (proportion of 
patients) in the dasiglucagon group . 
 
The special search category should incl ude the following MedDRA tems:  
 
Events of hypoglycemia  
- SMQ Hypoglycemia (narrow)  
 
Hemodynamic events  
- Zealand custom search  
- External file with PT to be provided by pharmacovigilance  
 
Allergic reactions  
- SMQ: Hypersensitivity (narrow)  
 
Events related to QT interval prolongation  
- SMQ: Torsade de pointes/QT prolongation (broad)  
 
Renal disorders  
- SMQ: Acute renal failure (broad)  
 
Hepatic disorders  

 
Zealand Pharma A/S   Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)  16 August 2019  
 
TMP -SOP -0202 -001-03_SAP Template  Page 26/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  - SMQ: Drug related hepatic disorders (broad)  
 
Medication errors  
- SMQ: Medication errors (broad)  
 
Rare events  
- Zealand custom search  
- External file with PTs to be provided by pharmacovigilance  
 
Injection site reactions  
- Zealand custom search  
- External file with PTs to be provided by pharmacovigilance  
 
 
All details of adverse events will be listed.  A separate listing for additional details for AEs of 
special interest is prepared.  
 
14.4 Clinical Laboratory Evaluation  
14.4.1  General  
 High (H)/Low (L) flags will be presented in laboratory listings  including the specific lab 
reference range , where appropriate. If normal ranges  are not available, the flagging 
cannot be performed.  
 All data will be listed in the CSR  as raw data. For the summaries the most recent value 
will be used in case several measurements have been performed at 1 visit.  
 
Tabulations will be prepared for each laboratory parameter  by treatment group : 
 
1. Laboratory results with continuous variables will be presented with descriptive statistics 
for each scheduled time point. They will be marked whether they are below (L), within or 
above (H) the respective reference range. The numbers in each category 
(above/below/within reference range) will be counted and percentages presented for each 
laboratory t est result , visit and time point . 
2. If laboratory values are categorical, the results (eg , positive/ negative) will be presented 
with counts and percentages for each visit and time point available.  
3. Presentation of “change from baseline ” values: Change from b aseline will be evaluated 
for all laboratory parameters. The change will be calculated by building the difference 
between the screening visit (V1) and the follow -up visit (V3). Change from baseline 
values will be presented with descriptive statistics in ca se of continuous parameters.  

 
Zealand Pharma A/S   Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)  16 August 2019  
 
TMP -SOP -0202 -001-03_SAP Template  Page 27/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  14.4.2  Hematology  
Tabulation will follow presentation as suggested in section 14.4.1 , items #1 to #3. No figures 
will be pre pared.  
14.4.3  Biochemistry  
Tabulation will follow presentation as suggested  in section 14.4.1 , items #1 to #3. No figures 
will be prepared.  
14.4.4  Coagulation  
Coagulation parameters at screening will be tabulated with descriptive statistics by treatment 
group.  
14.4.5   Urinalysis  
Tabulation will follow presentation as suggested  in section 14.4.1 , items #1 to #3. No figures 
will be prepared.  
14.4.6  Pregnancy test  
Data results of pregnancy test will be tabulated with counts/percentages for each visit by 
treatment group.  
14.4.7  Alcohol breath test  
Data on alcohol breath test  will be listed.  
14.5 Vital Signs  
Vital signs will be summarized using descriptive statistics at baseline and at each postbaseline 
time point.  
Categorical analysis of pulse rate  will be done using the following thresholds:  
 
 Class 1  Class 2  
Pulse rate  <=120 bpm  >120 bpm  
14.6 Physical Examination  
Physical examination results will be included in data listings only.  
14.7 Electrocardiogram  
The n umber of patients with normal/abnormal clinically significant/abnormal not clinically 
significant investigator assessments of 12 -lead ECG  will be tabulated with counts/percentages by 
treatment group  and visit .  

 
Zealand Pharma A/S   Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)  16 August 2019  
 
TMP -SOP -0202 -001-03_SAP Template  Page 28/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019   
Descriptive measures by visit for each ECG parameter will be presented by treatment group for 
each visit.  
 
In addition, a categorical summary of corrected QT interval  (QTc) values will be presented.  At 
each visit, the number of patients with QTc according to Fridericia ’s formula  (QTcF ) values of 
>450 ms, >480 ms, and >500 ms will be presented. At each postbaseline time point, the number 
of patients  with change from baseline values in QTcF of >30 ms and >60 ms will be presented.   
 
14.8 Immunogenicity  
Occurrence of ADA will be analyzed descriptively per treatment group. No statistical tests are 
planned.  
 
ADA will be derived from the number of patients havi ng an ADA -positive sample during the 
course of the trial. Determination of the number of patients will include counting:  
 
1. Patients, who were ADA -negative at baseline and ADA -positive after drug administration 
(=treatment -induced ADA patients)  
2. Baseline ADA -positive patients with significant increases (≥5 -fold) in ADA titer after 
drug administration  (= treatment -boosted  ADA patients)  
 
Both patient numbers will be summed up for the overall ADA incidence nominator. The 
nominator will be derived by dividing by the number of evaluable patients (see sec. Definitions: 
Evaluable patients = A patient  with at least one sample taken after drug administration during 
the treatment or follow -up that is appropriate for ADA testing (with reportable result). ). Patients, 
who were baseline -positive patients without any samples available after drug administration , will 
be excluded from the number of evaluable patients. Note that for ADA -positive patients 
unscheduled dosing visits are performed and results from those visits ha ve to be respe cted as 
well.  
15. CHANGES TO PROTOCOL -SPECIFIED ANALYSES  
The following changes have been made in the SAP compared to the protocol:  
 
- The statistical analyis for the primary efficacy parameter has been reworded and 
additional sensitivity and suppor tive analysis have been added.  
- For the secondary efficacy variables, the terminology was changed from ‘… within 30 
(20 or 15 or 10) min’ to ‘…at 30 (20  or 15 or 10) min’.  
 
 
 

 
Zealand Pharma A/S   Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)  16 August 2019  
 
TMP -SOP -0202 -001-03_SAP Template  Page 29/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  1. REFERENCES  
US Department of Health and Human Services  (DHHS) , Food  and Drug Administration, Center 
for Drug  Evaluation and Research (CDER).  Guidance for industry : E9 Statistical principles for 
clinical trials . September 1998  ICH [cited 2018 Aug 03]. Available from:  
https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryin formation/guidances/ucm
073137.pdf  
 
 

 
Zealand Pharma A/S   Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)  16 August 2019  
 
TMP -SOP -0202 -001-03_SAP Template  Page 30/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  2. APPENDICES  
Appendix A:  Presentation of Data  and Programming Specifications  
General   
 Specialized text styles, such as bold, italics, borders, shading, superscripted , and 
subscripted text will not be used in tables, figures, and data listings unless they add 
significant value to the table, figure, or data listing.  
 Only standard keyboard characters are to be used in tables and data listings.  
 Special characters, such as non-printable control characters, printer -specific, or font -
specific characters, will not be used on a table, figure, or data listing.  
 Hexadecimal character representations are allowed ( eg, µ, , ß). 
 All footnotes will be left justified and at the bottom o f a page. Footnotes must  be used 
sparingly and must add value to the table, figure, or data listing.  
 
Tables  
 Formal organization of tabulations may be changed during programming , if appropriate, 
eg, tables for the different variables may be combined into a  single table, or tables with 
more than  1 variable may be split into several tables.  
 Means and medians will be presented to  1 more decimal place than the raw data. 
Standard deviations will be presented to 2 more decimal places than the raw data. 
Minimums a nd maximums will be reported with the same number of decimal places as 
the raw data.  
 Percentages will be presented to the tenths place.  
 For frequency counts of categorical variables, categories whose counts are zero will be 
displayed for the sake of compl eteness.  
 For all inferential analyses, P values will be rounded to 3 decimal places (or at the 
highest level of prec ision) with a leading zero (0.0 01). P values less than 0.001 will be 
presented as “<0.0 01.” 
 The last footnote s will be  
- “Source : xxx”, where xxx indicates the source table  number (s) if applicable (in case aggregated 
results like mean or median are plotted) or the source listing(s) (in case individual responses are 
plotted) and/or source dataset (s) (eg, ADaM) .  
- “PROGRAM SOURCE: ... \\xx.sas , DATA  CUT OFF  DATE: DDMMMYYYY , RUN DATE: 
DDMMYY hh:mm”.  
where extract  date is the date  stamp of the data snapshot used.  
Figures  
 Legends will be used for all figures with more than  1 variable or item displayed.   
 Figures will be in black and white  but can be in color to add value to the clarity and 
readability of a figure. Lines must  be wide enough to see the line after being copied.  
 The last footnote s will be  
- “Source: xxx”, where xxx indicates the source listing number(s) and/or source dataset (s) (eg, ADaM).  
- “PROGRAM SOURCE: ... \\xx.sas, DATA CUT OFF  DATE: DDMMMYYYY, RUN DATE: 
DDMMYY hh:mm”.  

 
Zealand Pharma A/S   Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)  16 August 2019  
 
TMP -SOP -0202 -001-03_SAP Template  Page 31/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  where extract  date is the date  stamp of the data snapshot used.  
 
Listings  
 Formal organization of the listing may be changed during programming , if appropriate, 
eg, additio nal variables may be included, change in the column order, or the listing may 
be split into multiple parts due to space constraints.  
 If not otherwise specified, all data  listings will be sorted by treatment, center, patient 
number, visit, and date /time , as appropriate .  
 All date values will be presented in a SAS date ( eg, 29AUG2001) format.  
 All observed time values will be presented using a 24 -hour clock HH:MM:SS format ( eg, 
01:35:45 or 11:26). Seconds will only be reported if they were measured as part of  the 
study.  
 The last footnote will be  
- “PROGRAM SOURCE: ... \\xx.sas, DATA CUT OFF  DATE: DDMMMYYYY, RUN DATE: 
DDMMYY hh:mm”.  
where extract  date is the date  stamp of the data snapshot used.  
 
  

 
Zealand Pharma A/S   Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)  16 August 2019  
 
TMP -SOP -0202 -001-03_SAP Template  Page 32/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  Missing or incomplete dates ( ie, AEs and concomitant medications)  
The most conservative approach will be systematically considered. If the AE onset date is 
missing/incomplete, it is assumed to have occurred during the study treatment phase ( ie, 
considered a TEAE) except if the partial onset date or other data , such as th e stop date, indicates 
differently. Similarly, a medication with partial start and stop dates could be considered as both a 
prior and concomitant treatment.  
 
Standard Calculations  
 
Variables requiring calculation will be derived using the following formula s: 
 
Days – A duration expressed in days between  1 date (date1) and another later date (date2) is 
calculated using the formula  a follows : 
Duration in days = date2 – date1 + 1  
 
Months – A duration expressed in months is calculated using the INTCK function of  SAS as 
follows: months=intck('month','date1'd,date2'd, 'continuous') . 
 
Years – A duration expressed in years between  1 date (date1) and another later date (date2) is 
calculated as follows:  
Duration in years  = intck(‘year,'date1'd,date2'd, 'continuous').  
 
Height  – Height entries made in inches (in) are converted to centimeters (cm) using the 
following formula:  
Height (cm) = height (in) × 2.54. 
 
Weight – Weight entries made in pounds (lb) are converted to kilograms (kg) using the 
following formula:  
Weight ( kg) = w eight (lb)* 0.453592 . 
 
Temperature – Temperature entries in degrees Fahrenheit are converted to degrees centigrade  
using the following formula:  
Temperature  (degrees centigrade) = 5/9 × [temp erature  (degrees Fahrenheit) – 32]. 
 
Body Mass Index (BMI)  – BMI is calculated using height (cm) and weight (kg) using the 
following formula:  
BMI (kg/m2) = weight (kg)/[[height (cm)/100]2]. 
 
Change from baseline  – Change from baseline will be calculated as:  
Change = postbaseline value – baseline value . 
  

 
Zealand Pharma A/S   Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)  16 August 2019  
 
TMP -SOP -0202 -001-03_SAP Template  Page 33/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  Appendix  B: SAS Programming QC Requirements  
Programmer/ Validator Review  
 
1. Program Review  
1.1. Program name  follows standard naming conventions and is consistent with other 
study program names.  
1.2. Program header  uses standard template with all relevant information completed.  
1.3. Program flow  is logical ( ie, header → initialization code → macro variable definitions 
→ format definitions → main body).  
1.4. Programmer comments  are included throughout program to describe purp ose of 
individual sections or macros and provide understanding of specific code, if necessary. 
All comments are clear and up -to-date.  
1.5. Hard coding , if any, is implemented correctly and documented in program header 
with: date, reason, and reference to sponso r approval. A comment is also inserted at the 
location of the hard coding.  
1.6. SAP derivation rules , if any, are followed. Significant deviations from mock table or 
SAP text are documented in the SAS Program Header.  
1.7. Permanent intermediate datasets utilized as source data  have either been fully 
validated elsewhere or are fully validated within the scope of this QC .  
1.8. Program runs  properly and output dataset is generated as intended.  
 
2. SAS Log Review  
2.1. Scan of entire log confirming that each data step and procedure c ompleted properly.  
2.2. Critical messages  such as: errors, warnings, merge notes, or uninitialized variables are 
not found in log. Unavoidable critical messages are verified to not adversely affect the 
output and the reasons why they are unavoidable are documented.  
2.3. Other messages  such as “PUT” or  “INFO” messages (eg, overwritten variables 
following merge) are handled appropriately, if they are found in log.  
 
3. Output Review  
3.1. Output file name  follows standard naming conventions and is consistent with other 
study output file names.  
3.2. Titles and footnotes  are verified against mock table/listing/figure (if available). 
Discrepancies, including footnotes added for clarification, are noted and verified.  
3.3. Column/row header text  is verified against mock table/listing/figure and/or CRF.  
3.4. Format and sorting order  are correct relative to mock table/listings/figure and/or 
CRF.  
3.5. Pages breaks  are as intended throughout the document.  
3.6. Significant digits  are appropriate for summary results (eg, mean is 1 more digit than 
collected on the CRF).  
3.7. Analysis population totals  are verified as correct based on SAP definitions and are 
consistent with other tables using the same population(s).  
3.8. Inappropriate data:  checked for outliers, invalid numbers, missing results, etc.  
 

 
Zealand Pharma A/S   Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)  16 August 2019  
 
TMP -SOP -0202 -001-03_SAP Template  Page 34/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  4. Dataset Structure (for SDTM/TDM/A DaM) 
4.1. Pinnacle 21 validator is run.  Any errors or warnings are updated or explained.  
 
5. Verification of Data   
5.1. SDTM/TDM/Analysis datasets (A DaM or A DaM-Like)  
5.1.1.  Programmer  
 Each SDTM/TDM/Analysis dataset is opened and data are reviewed for 
consistency with the protocol, SAP, and/or  CRF (no additional QC programming 
is necessary).  
5.1.2.  Validator  
 Validation is performed against the protocol, SAP, and/or CRF. A spot -check of 
source data against the output dataset is performed on at least 2 patient s. Each 
CRF section/form should be populated  at least once for the spot -check. If a 
section/  form is repeated (eg , at several visits)  1 repeat per patient  has to be 
spotchecked.  
5.2. Tables  
5.2.1.  Program Review  
 Verify that the appropriate datasets, variables, analysis populations, 
parameters/tests, and visits/ time points are used.  
 Verify that all keyword and positional parameters of the standardized macro call 
are accurate and are implemented as intended.  
5.2.2.  Output Review  
 All expected data (parameters/tests, visits/time points, interventions, totals, etc.) 
are included on the output.  
 Units and the range of values are confirmed to be consistent.  
 Percentages are based on the correct denominator and confirmed to not exceed 
100%.  
 Counts within subgroups or subsets of data are checked for internal consistency 
(eg, subset counts do not exceed overall counts).  
5.3. Listings  
 Listing content is as expected (eg, listing includes all enrolled patient s, all 
expected visits)  
 Variables directly from source dataset are spot -checked for accuracy and 
completeness.  
 Derived or calcula ted variables are compared to corresponding source data and 
manual calculation for at least 2 patient s are done.  
5.4. Figures  
 Manual comparison to the corresponding table, where the table is validated and 
at least 25% of the data points on the figure are compar ed to the corresponding 
value on the table.  
 Manual calculations (if feasible based on small Ns or frequency counts).  
 

 
Zealand Pharma A/S   Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)  16 August 2019  
 
TMP -SOP -0202 -001-03_SAP Template  Page 35/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  6. Documentation  
6.1. The Programmer and Validator must document completion of QC (eg, date of QC and 
method used) in  BIO-0205 -TMP -002 Program Sta tus Document.  
6.2. Validator findings and/or comments may be tracked in the Program Status Document 
along with a description of how the finding was resolved and resolution date.  
6.3. The following must be retained electronically within the study folder by the Valida tor 
as supporting documentation:  
 If a spot -check of patient  data is performed, output that clearly identifies the 
patient s and CRF forms/sections that are checked  
 Pinnacle 21 report genera ted at time of QC including comments  
 

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
 
TMP -SOP -0202 -001-03_SAP Template  Page 36/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  Appendix C:  List of Tables , Figures , and Listings  
The following proposal for section 14 and 16.2  is completed according to ICH E3 guidelines.  The ICH heading number s and 
description are in bold . Minor changes from this planned index do not need to be amended in the SAP.    
 
Formal organization of tabulations may be changed during programming , if appropriate, eg, tables for the different variables may be 
combined into a single table, or tables with more than  1 variable may be split into several tables.  
 
  
 Section 14: Tables , Figures,  and Graphs   
Table  
Number  Table Title  Analysis 
Set Comment  
14 TABLES, FIGURES , AND GRAPHS REFERRED TO 
BUT NOT INCLUDED IN  THE TEXT    
14.1 DEMOGRAPHIC DATA    
14.1. 1 Patient number by country  All patients   
14.1.2  Patient number by country and center  All patients   
14.1.3  Patient disposition  All patients   
14.1.4  Trial termination form  Safety 
analysis set   
14.1.5  Demographic characteristics  Safety 
analysis set   
14.1.6  Demographic characteristics  FAS  
14.1. 7. Baseline characteristics    
14.1. 7.1 Diabetes history  Safety 
analysis set   
14.1. 7.2 Body measurements (height, weight, BMI)  Safety  

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
 
TMP -SOP -0202 -001-03_SAP Template  Page 37/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  Table  
Number  Table Title  Analysis 
Set Comment  
analysis set  
14.1.7 .3 BMI  by country  Safety 
analysis set   
14.1. 7.4 Medical history  Safety 
analysis set   
14.1. 8 Concomitant medication/ current diabetes treatment  Safety 
analysis set   
14.2 Efficacy data    
14.2.1  Primary efficacy endpoint    
14.2.1.1  Time to plasma gluc ose recovery - summary table  FAS Patients who receive IV glucose will 
be censored ( ie, set to ‘not recovered’) 
at 45 minutes after dosing  
14.2.1.2  Time to plasma glucose recovery - Kaplan Meier survival 
curve  FAS  
14.2.1.3  Time to plasma glucose recov ery - summary table  PP  
14.2.1.4  Time to plasma glucose recovery - Kaplan Meier  survival 
curve  PP  
14.2.1.5  Sensitivity analysis - time to plasma glucose recovery  without 
censoring for those subjects who require rescue IV glucose 
before 45 minutes  - summary table  FAS Without censoring for those subjects 
who require rescue IV glucose before 
45 minutes  
14.2.1.6  Sensitivity analysis - Time to p lasma glucose recovery 
without censoring for those subjects who require rescue IV 
glucose before 45 minutes  - Kaplan Meier  survival curve  FAS  
14.2.1. 7 Sensitivity analysis - time to plasma glucose recovery with 
censoring data at the actual time when the patients received 
glucose IV  - summary table  FAS With c ensoring data at the actual time 
when the patients received glucose IV.  
14.2.1. 8 Sensitivity analysis - Time to plasma glucose recovery with FAS  

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
 
TMP -SOP -0202 -001-03_SAP Template  Page 38/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  Table  
Number  Table Title  Analysis 
Set Comment  
censoring data at the actual time when the patients receive d 
glucose IV  - Kaplan Meier  survival curve  
14.2.1. 9 Time to plasma glucose recovery - histogram  FAS  
14.2.1. 10 Time to plasma gluc ose recovery – using linear interpolation of 
the time to recovery  – summary table  FAS  
14.2.1. 11 Time to plasma gluc ose recovery – using linear interpolation of 
the time to recovery – Kaplan Meier survival curve  FAS  
14.2.2  Secondary efficacy endpoin ts   
14.2.2 .1 Plasma glucose recovery within  10, 15, 20 and 30  minutes 
after trial product injection  FAS Including p-values from CMH or 
Fisher’s exact test and 95% CIs for 
response rates of each treatment group  
14.2.2.2  Plasma glucose - untransformed results at  10, 15, 20 and 30  
minutes after trial product injection  FAS  
14.2.2.3  Plasma glucose - change from baseline  results and  inferential 
test statistics at  10, 15, 20 and 30  minutes after trial product 
injection  FAS Results from ANCOVA will be 
displayed here  
    
14.3 Safety data    
14.3.1  Displays of Adverse Events    
14.3.1.1  Overall summary of adverse events  Safety 
analysis set   
14.3.1.2  TEAEs by system organ class and preferred term  Safety 
analysis set   
14.3.1.3  TEAEs of special interest by system organ class and preferred 
term Safety 
analysis set   
14.3.1.4  Other impotant TEAEs by system organ class and preferred 
term Safety 
analysis set   

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
 
TMP -SOP -0202 -001-03_SAP Template  Page 39/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  Table  
Number  Table Title  Analysis 
Set Comment  
14.3.1.5  TEAEs, which are injection site reactions  Safety 
analysis set   
14.3.1. 6 Study drug -related TEAEs  by system organ class and 
preferred term  Safety 
analysis set   
14.3.1. 7 TEAEs by system organ class and preferred term and causal 
relationship  Safety 
analysis set   
14.3.1. 8 TEAEs by system organ class and preferred term and severity  Safety 
analysis set   
14.3.1. 9 SAEs by system organ class and preferred term  Safety 
analysis set   
14.3.1. 10 Special search category TEAEs  Safety 
analysis set   
14.3.2  Listings of deaths, other serious and significant adverse events   This is a cross -reference to listing 
16.2.7.4  
14.3.3  Narratives of deaths, other serious and certain other significant 
adverse events   This is a cross -reference to section 
12.3.2 of the CSR  
14.3.4  Extent of exposure    
14.3.4 .1 Insulin administration prior to the hypoglycemia induction 
procedure  Safety 
analysis set   
14.3.4 .2 Hypoglycemia induction procedure  Safety 
analysis set   
14.3.4.3  Trial medication  Safety 
analysis set   
14.3.4.4  Post-treatment rescue glucose  infusion  Safety 
analysis set   
14.3.5  Other safety data    
14.3.5 .1 ECG    

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
 
TMP -SOP -0202 -001-03_SAP Template  Page 40/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  Table  
Number  Table Title  Analysis 
Set Comment  
14.3.5 .1.1 ECG, overall interpretation  Safety 
analysis set   
14.3.5.1.2  ECG, descriptive statistics of all ECG parameters  Safety 
analysis set   
14.3.5.1.3  ECG, categorical analysis of QTc results  Safety 
analysis set   
14.3.5.1.4  ECG, categorical analysis of QTc results , change from 
baseline  Safety 
analysis set   
14.3.5 .2 Laboratory data    
14.3.5.2.1  Hematology  Safety 
analysis set   
14.3.5.2.2  Clinical chemistry  Safety 
analysis set   
14.3.5.2.3  Coagulation  Safety 
analysis set   
14.3.5.2.4  Urinalysis - pH Safety 
analysis set   
14.3.5.2.5  Urinalysis - quantitative results, count of abnormal results  Safety 
analysis  set  
14.3.5.2.6  Pregnancy test    
14.3.5 .3 Local tolerability  Safety 
analysis set   
14.3.5 .4 Vital signs    
14.3.5 .5 Pulse rate  – categorical analysis  Safety 
analysis set   
14.3.5 .6 Immunogenicity - occurrence of ADA  Safety 
analysis set   

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
 
TMP -SOP -0202 -001-03_SAP Template  Page 41/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  Table  
Number  Table Title  Analysis 
Set Comment  
14.4 Pharmacokinetic ( PK) and pharmacodynamic (PD )   
14.4.1  Pharmacokinetics    
14.4.1.1  Summary statistics of plasma dasiglucagon and GlucaGen 
concentration table  FAS  
14.4.1.2  PK metrics  FAS  
14.4.1.3  Figure: Mean analyte concentrations versus time - original scale  FAS  
14.4.1.4  Figure: Mean analyte concentrations versus time - log scale  FAS  
14.4.1.5  Figure: Individual analyte concentrations versus time curves  - 
original scale  FAS  
14.4.2  Pharmacodynamics    
14.4.2.1  PD metrics  FAS  
14.4.2.2  Figure: Mean glucose concentrations versus time - original 
scale  FAS  
14.4.2.3  Figure: Individual glucose concentrations versus time curves  - 
original scale  FAS  
 
  

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
 
TMP -SOP -0202 -001-03_SAP Template  Page 42/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  Section 16.2: List of Data Listings  
ICH Listing  
Number   
Listing Title  Comment  
16.2 PATIENT DATA LISTINGS   
16.2.1  Discontinued patients   
16.2.1.1  Patient disposition   
16.2.1.2  Trial termination   
16.2.2  Protocol deviations   
16.2.2.1  Patient s not fulfilling any inclusion/exclusion criteria   
16.2.3  Patients excluded from the efficacy analysis   
16.2.3.1  Patients Excluded from analysis   
16.2.4  Demographic data   
16.2.4.1  Informed consent and d emographics   
16.2.4.2  Baseline characteristics  (body measurements)   
16.2.4.3  Diabetes history   
16.2.4.4  Medical history   
16.2.5  Compliance and/or drug concentration data   
16.2.5.1  Visit dates   
16.2.5.2  Randomisation   
16.2.5.3  Insulin administration prior to the hypoglycemia induction procedure   
16.2.5.4  Hypoglycemia induction procedure   
16.2.5.5  Study drug administration   
16.2.5.6  Post-treatment rescue glucose  infusion   
16.2.5.7  Plasma dasiglucagon /GlucaGen sampling and concentrations   
16.2.5.8  Plasma dasiglucagon /GlucaGen pharmacokinetic metrics   
16.2.6  Individual efficacy response data   
16.2.6 .1 Plasma glucose sampling and concentrations   

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
 
TMP -SOP -0202 -001-03_SAP Template  Page 43/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  ICH Listing  
Number   
Listing Title  Comment  
16.2. 6.2 Plasma g lucose pharmacodynamic metrics   
16.2. 6.3 Time to plasma glucose recovery  Derived 
including 
derived 
parameters  
16.2.7  Adverse events listings   
16.2.7.1  Adverse events - CRF entries   
16.2.7.2  Adverse events - MedDRA coding   
16.2.7.3  Adverse Event of Special Interest - additional details   
16.2.7.4  Death and s erious adverse events   
16.2.7. 5 Adverse events – leading to withdrawal from study   
16.2.7. 6 Adverse events – patients with positive ADA result   
16.2.7. 7 Adverse events - plasma glucose measurements in case of hypogylcemia   
16.2.8  Listing of individual laboratory measurements by patient, when required by regulatory 
authorities   
16.2.8.1  Hematology  incl. derived data CFB  
16.2.8.2  Biochemistry  incl. derived data CFB  
16.2.8.3  Coagulation  incl. derived data CFB  
16.2.8.4  Urinalysis   
16.2.8.5  Pregnancy test   
16.2.8.6  Alcohol breath test   
16.2.9  Other data   
16.2.9.1  Vital signs   
16.2.9.2  Physical examination   
16.2.9.3  Electrocardiogram  incl. derived data CFB  
16.2.9.4  Concomitant medication and current diabetes treatment   
16.2.9. 5 Local tolerability   

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
 
TMP -SOP -0202 -001-03_SAP Template  Page 44/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  ICH Listing  
Number   
Listing Title  Comment  
16.2.9.6  Immunogenicity results   
 

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
TMP -SOP -0202 -001-03_SAP Template  Page 45/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019   
Appendix D: Table  Layouts  
 
Zealand Pharma A/S  Clinical Study Report Section 14 
Protocol Number: ZP4207 -17086 Page 1 of 1 
14.1.1: Patient number by country , all patients  
 
Country Sreening Failure 
(N=xxx) dasiglucagon  
(N=xxx) Placebo 
(N=xxx) GlucaGen  
(N=xxx) Total 
(N=xxx) 
  
 Country 1    n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
Country 2    n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
...   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
       
 US   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
 NON-US   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
  
 
 
PROGRAM SOURCE:### , DATA CUT OFF DATE: ddmmmyyyy   RUN DATE: ddmmyyy hh:mm CET  
  

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
TMP -SOP -0202 -001-03_SAP Template  Page 46/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  Zealand Pharma A/S  Clinical Study Report Section 14 
Protocol Number: ZP4207 -17086 Page 1 of 1 
14.1.2: Patient number by country  and center , all patients  
 
Country  
Center Number  Sreening Failure  
 (N=xxx) dasiglucagon  
(N=xxx) Placebo 
(N=xxx) GlucaGen  
(N=xxx) Total 
(N=xxx) 
   
 Country 1  xx   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
  xx   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
       
Country 2  xx   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
 xx   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
...        
        
 Country xx  xx   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
  xx   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
   
 
PROGRAM SOURCE:### , DATA CUT OFF DATE: ddmmmyyyy   RUN DATE: ddmmyyy hh:mm CET  
 
 
  

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
TMP -SOP -0202 -001-03_SAP Template  Page 47/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  Zealand Pharma A/S  Clinical Study Report Section 14 
Protocol Number: ZP4207 -17086 Page 1 of 1 
14.1.3: Patient disposition , all patients  
 
Number of  Sreening Failure  
 (N=xxx) dasiglucagon  
(N=xxx) Placebo 
(N=xxx) GlucaGen  
(N=xxx) Total 
(N=xxx) 
  
 patients screened    n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
patients randomised        n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
patients in safety analysis set       n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
 patients in full analysis set       n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
 patients in per protocol set       n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
  
 
 
 
PROGRAM SOURCE:### , DATA CUT OFF DATE: ddmmmyyyy  RUN DATE: ddmmyyy hh:mm CET  
  

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
TMP -SOP -0202 -001-03_SAP Template  Page 48/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  Zealand Pharma A/S  Clinical Study Report Section 14 
Protocol Number: ZP4207 -17086 Page 1 of 1 
14.1.4: Trial termination , Safety analysis set  
 
 dasiglucagon  
(N=xxx) Placebo 
(N=xxx) GlucaGen  
(N=xxx) Total 
(N=xxx) 
 
Did the patient complete the study?  
 No   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
Yes   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
 
Primary reason for non -completion  
 Adverse event    n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
Death   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
...      
 
 
 
PROGRAM SOURCE:### , DATA CUT OFF DATE: ddmmmyyyy  RUN DATE: ddmmyyy hh:mm CET  
Programmer Note: Populate all possible reasons for non -completion from e -CRF

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
TMP -SOP -0202 -001-03_SAP Template  Page 49/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019   
Zealand Pharma A/S  Clinical Study Report Section 14 
Protocol Number: ZP4207 -17086 Page 1 of 2 
14.1.5: Demographic characteristics, Safety analysis set  
 
 dasiglucagon  
(N=xxx) Placebo 
(N=xxx) GlucaGen  
(N=xxx) Total 
(N=xxx) 
      
 Age     
 n xx xx xx xx 
Mean (SD)  xx.x (xx.xx) xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  
Median xx.x xx.x xx.x xx.x 
Min, Max  xx, xx xx, xx xx, xx xx, xx 
     
 Age groups      
   6-11 years   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
 12-17 years   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
     
 Gender     
   Male   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
 Female   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
     
 Child bearing potential      
   No   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
   Yes   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
     
      
 
 
 
 
PROGRAM SOURCE:### , DATA CUT OFF DATE: ddmmmyyyy   RUN DATE: ddmmyyy hh:mm CET  
 
  

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
TMP -SOP -0202 -001-03_SAP Template  Page 50/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  Zealand Pharma A/S  Clinical Study Report Section 14 
Protocol Number: ZP4207 -17086 Page 2 of 2 
14.1.5 Demographic characteristics, Safety analysis set  
 
 dasiglucagon  
(N=xxx) Placebo 
(N=xxx) GlucaGen  
(N=xxx) Total 
(N=xxx) 
      
 Race     
 American indian or alaska native    n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
 Asian   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
 ...   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
 ...   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
 ...   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
 ...   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
...   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
      
 Ethnic     
 Hispanic  or latino   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
Nothispanic  or latino   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
   Not allowed to ask per  local regulations    n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
      
 
 
 
 
PROGRAM SOURCE:### , DATA CUT OFF DATE: ddmmmyyyy   RUN DATE: ddmmyyy hh:mm CET  
Programmer Note: Populate all possible races  from e -CRF  

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
TMP -SOP -0202 -001-03_SAP Template  Page 51/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019   
Protocol Number: ZP4207 -17086 Page 1 of 2 
14.1.6: Demographic characteristics, FAS 
 
 Repetiton of table 14.1.5 with different selection of population.  
 If identical (like expected) it will be sufficient to state they are identical.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PROGRAM SOURCE:### , DATA CUT OFF DATE: ddmmmyyyy   RUN DATE: ddmmyyy hh:mm CET  
  

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
TMP -SOP -0202 -001-03_SAP Template  Page 52/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019   
Zealand Pharma A/S  Clinical Study Report Section 14 
Protocol Number: ZP4207 -17086 Page 1 of 1 
14.1.7.1: Diabetes history, Safety analysis set  
 
 dasiglucagon  
(N=xxx) Placebo 
(N=xxx) GlucaGen  
(N=xxx) Total 
(N=xxx) 
      
 Time since diagnosis of diabetes  1 [years]     
 n xx xx xx xx 
Mean (SD)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  
Median xx.x xx.x xx.x xx.x 
Min, Max  xx, xx xx, xx xx, xx xx, xx 
      
 
 
 
 
PROGRAM SOURCE:### , DATA CUT OFF DATE: ddmmmyyyy   RUN DATE: ddmmyyy hh:mm CET  
 
  

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
TMP -SOP -0202 -001-03_SAP Template  Page 53/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  Zealand Pharma A/S  Clinical Study Report Section 14 
Protocol Number: ZP4207 -17086 Page 1 of 1 
14.1.7.2: Body measurements (height, weight, BMI) , Safety analysis set  
 
 dasiglucagon  
(N=xxx) Placebo 
(N=xxx) GlucaGen  
(N=xxx) Total 
(N=xxx) 
      
 Height [cm]      
 n xx xx xx xx 
Mean (SD)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  
Median xx.x xx.x xx.x xx.x 
Min, Max  xx, xx xx, xx xx, xx xx, xx 
      
 Weight [kg]      
 n xx xx xx xx 
Mean (SD)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  
Median xx.x xx.x xx.x xx.x 
Min, Max  xx, xx xx, xx xx, xx xx, xx 
      
 Body mass index [kg/m2]      
 n xx xx xx xx 
Mean (SD)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  
Median xx.x xx.x xx.x xx.x 
Min, Max  xx, xx xx, xx xx, xx xx, xx 
      
 Body mass index class      
 <25 kg/m2   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
25-<30 kg/m2    n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
30-<35 kg/m2    n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
>35 kn/m2    n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
      
 
 
 
 
PROGRAM SOURCE:### , DATA CUT OFF DATE:  ddmmmyyyy   RUN DATE: ddmmyyy hh:mm CET  
 
  

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
TMP -SOP -0202 -001-03_SAP Template  Page 54/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019   
Zealand Pharma A/S  Clinical Study Report Section 14 
Protocol Number: ZP4207 -17086 Page 1 of 1 
14.1.7.3: BMI by country , Safety analysis set  
 
Country  dasiglucagon  
(N=xxx) Placebo 
(N=xxx) GlucaGen  
(N=xxx) Total 
(N=xxx) 
       
 Country 1  <25 kg/m2   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
 25-<30 kg/m2    n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
 30-<35 kg/m2    n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
 >35 kn/m2    n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
 ...      
       
 Country xx  <25 kg/m2   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
 25-<30 kg/m2    n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
 30-<35 kg/m2    n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
 >35 kn/m2    n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
       
 US <25 kg/m2   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
 25-<30 kg/m2    n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
 30-<35 kg/m2    n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
 >35 kn/m2    n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
       
 NON-US <25 kg/m2   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
 25-<30 kg/m2    n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
 30-<35 kg/m2    n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
 >35 kn/m2    n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
       
 
 
 
 
PROGRAM SOURCE:### , DATA CUT OFF DATE: ddmmmyyyy   RUN DATE: ddmmyyy hh:mm CET  
 
  

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
TMP -SOP -0202 -001-03_SAP Template  Page 55/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  Zealand Pharma A/S  Clinical Study Report Section 14 
Protocol Number: ZP4207 -17086 Page 1 of x 
14.1.8: Medical history , Safety analysis set  
 
 Number of Patients (%) Event Count  
 
System organ class  
Preferred term  dasiglucagon  
(N=xxx) Placebo 
(N=xxx) GlucaGen  
(N=xxx) Total 
(N=xxx) 
      
 Any medical history  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  
      
 SOC class 1      
 PT Term 1  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  
 PT Term 2 xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  
 PT Term 3  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  
 PT Term xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  
     
 SOC class 2      
 PT Term 1  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  
 PT Term 2  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  
 PT Term 3  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  
 PT Term xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  
     
 SOC class xx      
 PT Term 1  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  
 PT Term 2  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  
 PT Term 3  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  
 PT Term xx  xx ( xx.x) xx  xx ( xx.x) xx xx ( xx.x) xx  xx ( xx.x) xx  
...     
Note: At each level of summation ( SOC class, preferred name) , patients reporting more than  1 event are counted only once  for the patient count.  
Table is sorted by descending patientcount on the PT level  
Percentages are b ased on total no. of patients in each treatment group  
 
 
PROGRAM SOURCE:### , DATA CUT OFF DATE: ddmmmyyyy   RUN DATE: ddmmyyy hh:mm CET  
  

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
TMP -SOP -0202 -001-03_SAP Template  Page 56/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  Zealand Pharma A/S  Clinical Study Report Section 14 
Protocol Number: ZP4207 -17086 Page 1 of x 
14.1.8: Concomitant Medications/ Current Diabetes Treatment , Safety analysis set  
 
 Number of Subjects (%) Medication  Count 
 
ATC class (level 2)  
Preferred name  dasiglucagon  
(N=xxx) Placebo 
(N=xxx) GlucaGen  
(N=xxx) Total 
(N=xxx) 
      
 Any medication/ treatment  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  
      
 ATC class 1     
 PT Name 1 xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  
 PT Name 2 xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  
 PT Name 3 xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  
 PT Name xx xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  
     
 ATC class 2     
 PT Term 1  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  
 PT Name 2 xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  
 PT Name 3 xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  
 PT Name xx xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  
     
 ATC class xx      
 PT Name 1 xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  
 PT Name 2 xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  
 PT Name 3 xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  
 PT Name xx xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  
     
...     
 
Note: At each level of summation (overall, ATC class, preferred name) patients reporting more than  1 medication/ treatment  are counted only once . 
Table is sorted by descending total patient count  
Percentages are based on total no. of subjects in each treatment group  
 
PROGRAM SOURCE:### , DATA CUT OFF DATE: ddmmmyyyy   RUN DATE: ddmmyyy hh:mm CET  
  

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
TMP -SOP -0202 -001-03_SAP Template  Page 57/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  Zealand Pharma A/S  Clinical Study Report Section 14  
Protocol Number: ZP4207 -17086 Page 1 of 2  
14.2.1.1: Time to plasma glucose recovery - summary table, FAS  
Primary model  
 Treatment   
 dasiglucagon   
(N=xxx) GlucaGen  
(N=xx) placebo 
(N=xx)  
p-values 
     
Status (N)  Xx xx xx  
Recovered1  xx (xx.xx)  xx (xx.xx)  xx (xx.xx)   
Censored2 xx (xx.xx)  xx (xx.xx)  xx (xx.xx)   
     
Time to recovery (minutes)      
25th percentile  xx.x xx.x xx.x  
Median (95% CI) xx.x (xx.x ; xx.x)  xx.x (xx.x ; xx.x)  xx.x (xx.x ; xx.x)   
75th percentile  xx.x xx.x xx.x  
     
Dasiglucagon versus Placebo   P -value (log -
rank test – stratified)      
x.xxxx 
  P-value (log -rank test – non-stratified)     x.xxxx 
  P-value (Wilcoxon test) - stratified     x.xxxx 
     
Dasiglucagon versus GlucaGen  
  P-value (log -rank test – stratified)      
x.xxxx 
  P-value (log -rank test – non-stratified)     x.xxxx 
      
Cox proportional hazards3      
Hazard ratio  xx.xx xx.xx 1  
95% profile CL  (xx.xxx ; xx.xxx)  (xx.xxx ; xx.xxx)    
P-values     
Dasiglucagon versus Placebo     x.xxxx 
Dasiglucagon versus Glucagen     x.xxxx 
Glucagen versus Placebo     x.xxxx 
Type 3 test for Age     x.xxxx 
Type 3 test for injection site     x.xxxx 
1: Increase of plasma glucose of 20 mg/dL within 45 min without iv glucose  
2: Did not recover within 45 min or received iv glucose before 45 min  
3: Cox proportional hazard model with treatment, age and injection site as fixed effects and baseline plasma glucose as covariate  
  
PROGRAM SOURCE:### , DATA CUT OFF DATE: ddmmmyyyy   RUN DATE: ddmmyyy hh:mm CET   

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
TMP -SOP -0202 -001-03_SAP Template  Page 58/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  Zealand Pharma A/S  Clinical Study Report Section 14  
Protocol Number: ZP4207 -17086  Page 2 of 2  
 
Homogenicity models  
 
  Treatment   
 dasiglucagon   
(N=xxx) GlucaGen  
(N=xx) placebo 
(N=xx) 
    
Cox proportional hazards1     
<Sub-group level 1>     
Hazard ratio  xx.xx xx.xx 1 
95% profile CL  (xx.xxx ; xx.xxx)  (xx.xxx ; xx.xxx)   
<Sub-group level 2>     
Hazard ratio  xx.xx xx.xx 1 
95% profile CL  (xx.xxx ; xx.xxx)  (xx.xxx ; xx.xxx)   
.. .    
    
<Sub-group level i >    
Hazard ratio  xx.xx xx.xx 1 
95% profile CL  (xx.xxx ; xx.xxx)  (xx.xxx ; xx.xxx)   
    
 
1: Cox proportional hazard model with treatment, age and injection site as fixed effects and baseline plasma glucose as covariate  
 
 
  

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
TMP -SOP -0202 -001-03_SAP Template  Page 59/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  Zealand Pharma A/S  Clinical Study Report Section 14  
Protocol Number: ZP4207 -17086 Page 1 of x  
14.2.1.2: Time to plasma glucose recovery - Kaplan Meier  survival curve , FAS 
  
 
 
 
Note: this is a generic example using example data from SAS Institute; number of patients at risk are adapted to 0, 10, 15, 20, 30 and 45min.  
 
PROGRAM SOURCE:### , DATA CUT OFF DATE: ddmmmyyyy   RUN DATE: ddmmyyy hh:mm CET  
  


 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
TMP -SOP -0202 -001-03_SAP Template  Page 60/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  Zealand Pharma A/S  Clinical Study Report Section 14  
Protocol Number: ZP4207 -17086 Page 1 of x  
14.2.1.3: Time to plasma glucose recovery - summary table, PP 
  
 
 Repetiton of table 14.2.1.1 with different selection of population.  Only page 1 output presented here.  
  

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
TMP -SOP -0202 -001-03_SAP Template  Page 61/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  Zealand Pharma A/S  Clinical Study Report Section 14  
Protocol Number: ZP4207 -17086 Page 1 of x  
14.2.1.4: Time to plasma glucose recovery - Kaplan Meier survival curve , PP 
  
 
 Repetiton of table 14.2.1. 2 with different selection of population.  
  

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
TMP -SOP -0202 -001-03_SAP Template  Page 62/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  Zealand Pharma A/S  Clinical Study Report Section 14  
Protocol Number: ZP4207 -17086 Page 1 of x  
14.2.1.5: Sensitivity analysis - time to plasma glucose recovery  without censoring for those subjects who require rescue IV glucose before 45 minutes  - 
summary table , FAS 
  
 
 Repetiton of table 14.2.1.1 with different selection of population.  Only page 1 output presented here.  
  

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
TMP -SOP -0202 -001-03_SAP Template  Page 63/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  Zealand Pharma A/S  Clinical Study Report Section 14  
Protocol Number: ZP4207 -17086 Page 1 of x  
14.2.1.6: Sensitivity analysis - time to plasma glucose recovery without censoring for those subjects who require rescue IV glucose before 45 minutes - 
Kaplan Meier survival curve , FAS 
  
 
 Repetiton of table 14.2.1.2 with different selection of population.  
  

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
TMP -SOP -0202 -001-03_SAP Template  Page 64/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  Zealand Pharma A/S  Clinical Study Report Section 14  
Protocol Number: ZP4207 -17086 Page 1 of x  
14.2.1.7: Sensitivity analysis - time to plasma glucose recovery  with censoring for those subjects who require rescue IV glucose before 45 minutes  - 
summary table , FAS 
  
 
 Repetiton of table 14.2.1.1 with different selection of population . Only page 1 output presented here.  
  

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
TMP -SOP -0202 -001-03_SAP Template  Page 65/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  Zealand Pharma A/S  Clinical Study Report Section 14  
Protocol Number: ZP4207 -17086 Page 1 of x  
14.2.1.8: Sensitivity analysis - time to plasma glucose recovery with censoring for those subjects who require rescue IV glucose before 45 minutes - 
Kaplan Meier survival curve , FAS 
  
 
 Repetiton of table 14.2.1.2 with different selection of population.  
  

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
TMP -SOP -0202 -001-03_SAP Template  Page 66/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019   
Zealand Pharma A/S  Clinical Study Report Section 14  
Protocol Number: ZP4207 -17086 Page 1 of x  
14.2.1.9: Time to plasma glucose recovery - histogram , FAS 
  
 Layout will be established during programming  
  

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
TMP -SOP -0202 -001-03_SAP Template  Page 67/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  Zealand Pharma A/S  Clinical Study Report Section 14  
Protocol Number: ZP4207 -17086 Page 1 of x  
14.2.1.10: Time to plasma glucose recovery - using linear interpolation of the time to recovery , FAS 
  
 
 Repetiton of table 14.2.1.1 using linear interpolated time to recovery data. Only page 1 output presented here.  
  

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
TMP -SOP -0202 -001-03_SAP Template  Page 68/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  Zealand Pharma A/S  Clinical Study Report Section 14 
Protocol Number: ZP4207 -17086 Page 1 of 1 
14.2.2.1 : Plasma glucose recovery within 10, 15, 20 and 30 minutes after trial product injection , FAS 
 
 dasiglucagon  
(N=xxx) Placebo 
(N=xxx) GlucaGen  
(N=xxx) p-value1 
dasiglucgon  
versus  
Placebo 
      
 Plasma glucose recovery within 10 min     
   No   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)      
   Yes   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)    
95% CIs for response rate (Category ‘Yes’)  [xx.x; xx.x]  [xx.x; xx.x]  [xx.x; xx.x]  x.xxxx 
      
 Plasma glucose recovery within 15min      
   No   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)      
   Yes   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)    
95% CIs for response rate (Category ‘Yes’)  [xx.x; xx.x]  [xx.x; xx.x]  [xx.x; xx.x]  x.xxxx 
      
 Plasma glucose recovery within 2 0min     
   No   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)      
   Yes   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)    
95% CIs for response rate (Category ‘Yes’) [xx.x; xx.x]  [xx.x; xx.x]  [xx.x; xx.x]  x.xxxx 
      
 Plasma glucose recovery within 3 0min     
   No   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)      
   Yes   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)    
95% CIs for response rate (Category ‘Yes’)  [xx.x; xx.x]  [xx.x; xx.x]  [xx.x; xx.x]  x.xxxx 
      
 
 
If a patient has received an IV glucose treatment before recovery, the p atient is set to ‘not recovered’.  
1 p-values calculated using a Cochran-Mantel-Haenszel test stratified by age group and injection site . 
 
PROGRAM SOURCE:### , DATA CUT OFF DATE: ddmmmyyyy   RUN DATE: ddmmyyy hh:mm CET  
  

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
TMP -SOP -0202 -001-03_SAP Template  Page 69/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  Zealand Pharma A/S  Clinical Study Report Section 14 
Protocol Number: ZP4207 -17086 Page 1 of 1 
 
14.2.2.2 : Plasma glucose - untransformed results at 10, 15, 20  and 30 minutes after trial product injection  
 
 
Variable   
Time Point   dasiglucagon  
(N=xxx) Placebo 
(N=xxx) GlucaGen  
(N=xxx) Total 
(N=xxx) 
       
Result Pre-dose n xx xx xx xx 
  Mean (SD)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  
  Median xx.x xx.x xx.x xx.x 
  Min, Max  xx, xx xx, xx xx, xx xx, xx 
       
 10 min after dosing  n xx xx xx xx 
  Mean (SD)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  
  Median xx.x xx.x xx.x xx.x 
  Min, Max  xx, xx xx, xx xx, xx xx, xx 
       
 15 min after dosing  n xx xx xx xx 
  Mean (SD)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  
  Median xx.x xx.x xx.x xx.x 
  Min, Max  xx, xx xx, xx xx, xx xx, xx 
       
 20 min after dosing  n xx xx xx xx 
  Mean (SD)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx) xx.x (xx.xx)  
  Median xx.x xx.x xx.x xx.x 
  Min, Max  xx, xx xx, xx xx, xx xx, xx 
       
 30 min after dosing  n xx xx xx xx 
  Mean (SD)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  
  Median xx.x xx.x xx.x xx.x 
  Min, Max  xx, xx xx, xx xx, xx xx, xx 
       
 
If the rescue IV glucose was administered before 10, 15, 20, or 30 minutes, respectively, the patient’s plasma glucose change s from baseline is determined from the 
value at the time of rescue IV glucose administration . 
 
PROGRAM SOURCE:### , DATA CUT OFF DATE: ddmmmyyyy   RUN DATE: ddmmyyy hh:mm CET  
  

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
TMP -SOP -0202 -001-03_SAP Template  Page 70/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  Zealand Pharma A/S  Clinical Study Report Section 14 
Protocol Number: ZP4207 -17086 Page 2 of 2 
 
14.2.2.2 : Plasma glucose - change from baseline results and inferential test statistics at 10, 15, 20 and 30 minutes after trial product 
injection  
 
Variable   
Time Point   
dasiglucagon  
(N=xxx) Placebo 
(N=xxx) GlucaGen  
(N=xxx) Total 
(N=xxx) p-value1 
(95% CI) 
dasiglucgon  
versus  
Placebo 
        
Change from Baseline  10 min after dosing  n xx xx xx xx  
  Mean (SD)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)   
  Median xx.x xx.x xx.x xx.x  
  Min, Max  xx, xx xx, xx xx, xx xx, xx x.xxxx 
  LS-mean xx.xx xx.xx xx.xx xx.xx xx.xx 
  95%CI (LS -mean) [xx.x; xx.x] [xx.x; xx.x]  [xx.x; xx.x]  [xx.x; xx.x]  [xx.x; xx.x]  
        
 15 min after dosing  N xx xx xx xx  
  Mean (SD)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)   
  Median xx.x xx.x xx.x xx.x  
  Min, Max  xx, xx xx, xx xx, xx xx, xx x.xxxx 
  LS-mean xx.xx xx.xx xx.xx xx.xx xx.xx 
  95%CI (LS -mean) [xx.x; xx.x]  [xx.x; xx.x]  [xx.x; xx.x]  [xx.x; xx.x]  [xx.x; xx.x]  
        
 20 min after dosing  n xx xx xx xx  
  Mean (SD)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)   
  Median xx.x xx.x xx.x xx.x  
  Min, Max  xx, xx xx, xx xx, xx xx, xx x.xxxx 
  LS-mean xx.xx xx.xx xx.xx xx.xx xx.xx 
  95%CI (LS -mean) [xx.x; xx.x]  [xx.x; xx.x]  [xx.x; xx.x]  [xx.x; xx.x]  [xx.x; xx.x]  
        
 30 min after dosing  n xx xx xx xx  
  Mean (SD)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)   
  Median xx.x xx.x xx.x xx.x  
  Min, Max  xx, xx xx, xx xx, xx xx, xx x.xxxx 
  LS-mean xx.xx xx.xx xx.xx xx.xx xx.xx 
  95%CI (LS -mean) [xx.x; xx.x]  [xx.x; xx.x]  [xx.x; xx.x]  [xx.x; xx.x]  [xx.x; xx.x]  
        
If the rescue IV glucose was administered before 10, 15, 20, or 30 minutes, respectively, the patient’s plasma glucose change s from baseline is determined from the 
value at the time of rescue IV glucose administration . 
1 p-values calculated using a n analysis of variance (ANOVA) with factors treatment, age group and injection site  
PROGRAM SOURCE:### , DATA CUT OFF DATE: ddmmmyyyy   RUN DATE: ddmmyyy hh:mm CET  
 
Zealand Pharma A/S  Clinical Study Report Section 14 

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
TMP -SOP -0202 -001-03_SAP Template  Page 71/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  Protocol Number: ZP4207 -17086 Page 1 of 1 
14.3.1.1: Overall summary of adverse events , Safety analysis set  
 
 Number of Subjects (%) Event Count  
 
 dasiglucagon  
(N=xxx) Placebo 
(N=xxx) GlucaGen  
(N=xxx) Total 
(N=xxx) 
      
 Adverse events during screening  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x)  xx xx ( xx.x) xx  
 Treatment -emergent AEs (TEAEs)  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  
 TEAEs, which are adverse events of special interest  (AESIs) xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  
 TEAEs, which are anothe r important event  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  
 TEAEs, which are injection site reactions  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  
 Study drug -related TEAEs 1 xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx 
 Serious TEAEs (SAEs)  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  
 Study drug -related serious TEAEs  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  
 Deaths xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  
      
...      
 
¹ Study drug -related TEAEs: TEAEs which were assessed by the investigator as possibly related or probably related, or without assessment o f relationship . 
Table is based on number of verbatims.  
Patients reporting more than  1 event are counted only once  for the patient count.  
Percentages are b ased on total no. of subjects in each treatment group  
 
PROGRAM SOURCE:### , DATA CUT OFF DATE: ddmmmyyyy   RUN DATE: ddmmyyy hh:mm CET  
  

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
TMP -SOP -0202 -001-03_SAP Template  Page 72/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  Zealand Pharma A/S  Clinical Study Report Section 14 
Protocol Number: ZP4207 -17086 Page 1 of x 
14.3.1.2 : TEAEs by system organ class and preferred term , Safety analysis set  
 
 Number of Subjects (%) Event Count  
 
System organ class  
Preferred term  dasiglucagon  
(N=xxx) Placebo 
(N=xxx) GlucaGen  
(N=xxx) Total 
(N=xxx) 
      
 Any adverse event xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  
      
 SOC class 1      
 PT Term 1  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  
 PT Term 2  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  
 PT Term 3  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  
 PT Term xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  
     
 SOC class 2      
 PT Term 1  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  
 PT Term 2  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  
 PT Term 3  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  
 PT Term xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  
     
 SOC class xx      
 PT Term 1  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  
 PT Term 2  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  
 PT Term 3  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  
 PT Term xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  
...     
 
Note: At each level of summation ( SOC class, preferred name) patients reporting more than  1 event are counted only once  for the patient count.  
Table is sorted by descending subject count on the PT level  in the dasiglucagon group.  
Percentages are b ased on total no. of subjects in each treatme nt group  
 
 
PROGRAM SOURCE:### , DATA CUT OFF DATE: ddmmmyyyy   RUN DATE: ddmmyyy hh:mm CET  
  

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
TMP -SOP -0202 -001-03_SAP Template  Page 73/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  Zealand Pharma A/S  Clinical Study Report Section 14 
Protocol Number: ZP4207 -17086 Page 1 of x 
14.3.1.3 : TEAEs of special interest by system organ class and preferred term , Safety analysis set  
 
 Repetiton of table 14.3.1.2 with different selection of the AE anal ysis dataset.  
  

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
TMP -SOP -0202 -001-03_SAP Template  Page 74/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  Zealand Pharma A/S  Clinical Study Report Section 14 
Protocol Number: ZP4207 -17086 Page 1 of x 
14.3.1.4 : Other impo rtant TEAEs by system organ class and preferred term , Safety analysis set  
 
 Repetiton of table 14.3.1.2 with different selection of the AE anaylsis y dataset.  
  

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
TMP -SOP -0202 -001-03_SAP Template  Page 75/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  Zealand Pharma A/S  Clinical Study Report Section 14 
Protocol Number: ZP4207 -17086 Page 1 of x 
14.3.1.5 : TEAEs, which are injection site reactions , Safety analysis set  
 
 Repetiton of table 14.3.1.2 with different selection of the AE ana lysis dataset.  
  

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
TMP -SOP -0202 -001-03_SAP Template  Page 76/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  Zealand Pharma A/S  Clinical Study Report Section 14 
Protocol Number: ZP4207 -17086 Page 1 of x 
14.3.1.6: Study drug -related TEAEs  by system organ class and preferred term , Safety analysis set  
 
 Repetiton of table 14.3.1.2 with different selection of the AE anaylsis y dataset.  
  

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
TMP -SOP -0202 -001-03_SAP Template  Page 77/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  Zealand Pharma A/S  Clinical Study Report Section 14 
Protocol Number: ZP4207 -17086 Page 1 of x 
14.3.1.7: TEAEs by system organ class and preferred term and causal relationship , Safety analysis set  
 
 
 dasiglucagon  
(N=xxx) Placebo 
(N=xxx) GlucaGen  
(N=xxx) 
System organ class  
Preferred term  Related1 Not Related2 Related1 Not Related2 Related1 Not Related2  
        
 Any adverse event  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  
        
 SOC class 1        
 PT Term 1  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  
 PT Term 2  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  
 PT Term 3  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  
 PT Term xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  
        
 SOC class 2        
 PT Term 1  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  
 PT Term 2  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  
 PT Term 3  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  
 PT Term xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  
        
---        
 
 
Note: At each level of summation ( SOC class, preferred name) patients reporting more than  1 event are counted only once  for the patient count.  
[1] Includes all events reported as ‘Possible ’, ‘Probable’ or missing relationship.  
[2] Includes all events reported as ‘Not related or  ‘Unlikely ’. 
Table is sorted by descending subject count on the PT level  in the dasiglucagon group . 
Percentages are b ased on total no. of subjects in each treatment group . 
 
 
PROGRAM SOURCE:### , DATA CUT OFF DATE: ddmmmyyyy   RUN DATE: ddmmyyy hh:mm CET  
  

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
TMP -SOP -0202 -001-03_SAP Template  Page 78/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  Zealand Pharma A/S  Clinical Study Report Section 14 
Protocol Number: ZP4207 -17086 Page 1 of x 
14.3.1.8: TEAEs by system organ class and preferred term and severity , Safety analysis set  
 
 
 dasiglucagon  
(N=xxx) Placebo 
(N=xxx) GlucaGen  
(N=xxx) 
System organ class  
Preferred term  Mild Moderate  Severe Mild Moderate  Severe Mild Moderate   Severe  
            
 Any adverse event xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx   
            
 SOC class 1            
 PT Term 1  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx   
 PT Term 2  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx   
 PT Term 3  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx   
 PT Term xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx   
            
 SOC class 2            
 PT Term 1  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx   
 PT Term 2  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx   
 PT Term 3  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx   
 PT Term xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx  xx ( xx.x) xx   
            
 
 
Note: At each level of summation ( SOC class, preferred name) patients reporting more than  1 event are counted only once  for the patient count.  
Table is sorted by descending subject count on the PT level  in the dasiglucagon group.  
Percentages are b ased on total no. of subjects in each treatment group . 
 
 
PROGRAM SOURCE:### , DATA CUT OFF DATE: ddmmmyyyy   RUN DATE: ddmmyyy hh:mm CET  
  

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
TMP -SOP -0202 -001-03_SAP Template  Page 79/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  Zealand Pharma A/S  Clinical Study Report Section 14 
Protocol Number: ZP4207 -17086 Page 1 of x 
14.3.1.9: SAEs by system organ class and preferred term , Safety analysis set  
 
 Repetiton of table 14.3.1.2 with different selection of the AE anaylsis y dataset.  
  

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
TMP -SOP -0202 -001-03_SAP Template  Page 80/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019   
Zealand Pharma A/S  Clinical Study Report Section 14 
Protocol Number: ZP4207 -17086 Page 1 of x 
14.3.1.10 : Special search category TEAEs , Safety analysis set  
 
 Repetiton of table 14.3.1.2 with different selection of the AE anaylsisy dataset.  
 
  

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
TMP -SOP -0202 -001-03_SAP Template  Page 81/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  Zealand Pharma A/S  Clinical Study Report Section 14 
Protocol Number: ZP4207 -17086 Page 1 of x 
14.3.2: Listings of deaths, other serious and significant adverse events , Safety analysis set  
 
Please refer to listing 16.2.7.4.  
 
 
 
 
 
 
 
 
Programmer Note: Create a empty table with that reference as message   
  

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
TMP -SOP -0202 -001-03_SAP Template  Page 82/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  Zealand Pharma A/S  Clinical Study Report Section 14 
Protocol Number: ZP4207 -17086 Page 1 of x 
14.3.3: Narratives of deaths, other serious and certain other significant adverse events , Safety analysis set  
 
Please refer to listing 16.2.7.4.  
 
 
 
 
 
 
 
 
Programmer Note: Create a empty table with that reference as message   
  

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
TMP -SOP -0202 -001-03_SAP Template  Page 83/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  Zealand Pharma A/S  Clinical Study Report Section 14 
Protocol Number: ZP4207 -17086 Page 1 of 1 
14.3.4.1: Insulin administration prior to the hypoglycemia induction procedure , Safety analysis set  
 
 dasiglucagon  
(N=xxx) Placebo 
(N=xxx) GlucaGen  
(N=xxx) Total 
(N=xxx) 
 
Is the subject using multiple daily injections?  
 No   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
Yes   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
 Missing   n             n             n             n           
      
Has the subject taken insulin NPH ? 
 No   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
Yes   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
 Missing   n             n             n             n           
      
Is the subject using an insulin pump?  
 No   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
Yes   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
 Missing   n             n             n             n           
      
Was insulin glulisine (Apidra) administered in the 
last 5 hours prior to initiation of the hypoglycemic  
induction procedure?  
 No   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
Yes   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
 Missing   n             n             n             n           
      
 
 
PROGRAM SOURCE:### , DATA CUT OFF DATE: ddmmmyyyy  RUN DATE: ddmmyyy hh:mm CET  
 
  

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
TMP -SOP -0202 -001-03_SAP Template  Page 84/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  Zealand Pharma A/S  Clinical Study Report Section 14 
Protocol Number: ZP4207 -17086 Page 1 of 1 
14.3.4.2: Hypoglycemia induction procedure , Safety analysis set  
 
 dasiglucagon  
(N=xxx) Placebo 
(N=xxx) GlucaGen  
(N=xxx) Total 
(N=xxx) 
 
Was the hypoglycemi a induction procedure performed ? 
 No   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
Yes   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
 Missing   n             n             n             n           
      
Total amount of insulin administered to induce hypoglycemia  [IU] 
 n  xx xx xx xx 
 Mean (SD)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  
 Median xx.x xx.x xx.x xx.x 
 Min, Max  xx, xx xx, xx xx, xx xx, xx 
      
Total amount of glucose administered during the induction procedure  [mL] 
 n  xx xx xx xx 
 Mean (SD)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  
 Median xx.x xx.x xx.x xx.x 
 Min, Max  xx, xx xx, xx xx, xx xx, xx 
      
 
 
PROGRAM SOURCE:### , DATA CUT OFF DATE: ddmmmyyyy  RUN DATE: ddmmyyy hh:mm CET  
 
  

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
TMP -SOP -0202 -001-03_SAP Template  Page 85/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  Zealand Pharma A/S  Clinical Study Report Section 14 
Protocol Number: ZP4207 -17086 Page 1 of 1 
14.3.4.3: Trial medication , Safety analysis set  
 
 dasiglucagon  
(N=xxx) Placebo 
(N=xxx) GlucaGen  
(N=xxx) Total 
(N=xxx) 
 
Was the trial medication administered?  
 No   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
Yes   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
 Missing   n             n             n             n           
      
 
 
PROGRAM SOURCE:### , DATA CUT OFF DATE: ddmmmyyyy  RUN DATE: ddmmyyy hh:mm CET  
 
  

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
TMP -SOP -0202 -001-03_SAP Template  Page 86/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  Zealand Pharma A/S  Clinical Study Report Section 14 
Protocol Number: ZP4207 -17086 Page 1 of 1 
14.3.4.4: Post-treatment rescue glucose infusion , Safety analysis set  
 
 dasiglucagon  
(N=xxx) Placebo 
(N=xxx) GlucaGen  
(N=xxx) Total 
(N=xxx) 
 
Was glucose given for rescue ? 
 No   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
Yes   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
 Missing   n             n             n             n           
      
Time to first IV glucose infusion  [min] 
 Mean (SD)  n xx xx xx 
 Median Mean (SD)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  
 Min, Max  Median xx.x xx.x xx.x 
  Min, Max  xx, xx xx, xx xx, xx 
      
 
 
PROGRAM SOURCE:### , DATA CUT OFF DATE: ddmmmyyyy  RUN DATE: ddmmyyy hh:mm CET  
 
  

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
TMP -SOP -0202 -001-03_SAP Template  Page 87/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  Zealand Pharma A/S  Clinical Study Report Section 14 
Protocol Number: ZP4207 -17086 Page 1 of 2 
14.3.5.1.1: ECG, overall interpretation , Safety analysis set  
 
Visit  
Time Point   
Result dasiglucagon  
(N=xxx) Placebo 
(N=xxx) GlucaGen  
(N=xxx) Total 
(N=xxx) 
        
 Screening   NORMAL   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
   ABNORMAL / NOT CLIN. SIG.    n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
   ABNORMAL / CLIN. SIG.    n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
        
 Dosing Pre-dose NORMAL   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
   ABNORMAL / NOT CLIN. SIG.   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
   ABNORMAL / CLIN. SIG.    n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
        
 Dosing 20min post dose  NORMAL   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
   ABNORMAL / NOT CLIN. SIG.    n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
   ABNORMAL / CLIN. SIG.    n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
        
 Dosing 35min post dose  NORMAL   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
   ABNORMAL / NOT CLIN. SIG.    n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
   ABNORMAL / CLIN. SIG.    n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
        
 Dosing 45min post dose  NORMAL   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
   ABNORMAL / NOT CLIN. SIG.    n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
   ABNORMAL / CLIN. SIG.    n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
        
 Dosing 60min post dose  NORMAL   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
   ABNORMAL / NOT CLIN. SIG.    n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
   ABNORMAL / CLIN. SIG.    n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
        
 Dosing 300min post dose  NORMAL   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
   ABNORMAL / NOT CLIN. SIG.    n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
   ABNORMAL / CLIN. SIG.    n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
        
 
PROGRAM SOURCE:### , DATA CUT OFF DATE: ddmmmyyyy   RUN DATE: ddmmyyy hh:mm CET  
  

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
TMP -SOP -0202 -001-03_SAP Template  Page 88/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  Zealand Pharma A/S  Clinical Study Report Section 14 
Protocol Number: ZP4207 -17086 Page 2 of 2 
14.3.5.1.1: ECG, overall interpretation , Safety analysis set  
 
Visit  
Time Point   
Result dasiglucagon  
(N=xxx) Placebo 
(N=xxx) GlucaGen  
(N=xxx) Total 
(N=xxx) 
        
 Follow up   NORMAL   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
   ABNORMAL / NOT CLIN. SIG.    n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
   ABNORMAL / CLIN. SIG.    n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
        
 
PROGRAM SOURCE:### , DATA CUT OFF DATE: ddmmmyyyy   RUN DATE: ddmmyyy hh:mm CET  
  

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
TMP -SOP -0202 -001-03_SAP Template  Page 89/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  Zealand Pharma A/S  Clinical Study Report Section 14 
Protocol Number: ZP4207 -17086 Page 1 of x 
14.3.5.1.2: ECG, descriptive statistics of all ECG parameters , Safety analysis set  
 
 
Parameter  
Visit/ TimePoint    
Result dasiglucagon  
(N=xxx) Placebo 
(N=xxx) GlucaGen  
(N=xxx) Total 
(N=xxx) 
         
Mean heart rate 
[bpm]  Screening   n xx xx xx xx 
    Mean (SD)  xx.x (xx.xx) xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  
    Median xx.x xx.x xx.x xx.x 
    Min, Max  xx, xx xx, xx xx, xx xx, xx 
         
  Dosing/ Pre -dose  n xx xx xx xx 
    Mean (SD)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  
    Median xx.x xx.x xx.x xx.x 
    Min, Max  xx, xx xx, xx xx, xx xx, xx 
         
  Dosing/20 min 
after dosing   n xx xx xx xx 
    Mean (SD)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  
    Median xx.x xx.x xx.x xx.x 
    Min, Max  xx, xx xx, xx xx, xx xx, xx 
         
         
  ...       
         
  Follow up   n xx xx xx xx 
    Mean (SD)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  
    Median xx.x xx.x xx.x xx.x 
    Min, Max  xx, xx xx, xx xx, xx xx, xx 
         
 
PROGRAM SOURCE:### , DATA CUT OFF DATE: ddmmmyyyy   RUN DATE: ddmmyyy hh:mm CET  
Programmer Note: This table is continued for each of the following ECG parameter: PR Interval Aggregate  [msec], QRS Duration 
Aggregate [msec],  QT Interval Aggregate [msec],  QTcF Interval Aggregate [msec]  
  

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
TMP -SOP -0202 -001-03_SAP Template  Page 90/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019   
Zealand Pharma A/S  Clinical Study Report Section 14 
Protocol Number: ZP4207 -17086 Page 1 of x 
14.3.5.1.3: ECG, categorical analysis of QTc results , Safety analysis set  
 
Visit  
Time Point   
Result dasiglucagon  
(N=xxx) Placebo 
(N=xxx) GlucaGen  
(N=xxx) Total 
(N=xxx) 
        
 Screening   QTcF values of >450 ms    n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
   QTcF values of >4 80 ms   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
   QTcF values of >50 0 ms   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
        
 Dosing Pre-dose QTcF values of >450 ms    n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
   QTcF values of >4 80 ms   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
   QTcF values of >50 0 ms   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
        
 Dosing 20min post dose  QTcF values of >450 ms    n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
   QTcF values of >4 80 ms   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
   QTcF values of >50 0 ms   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
        
 ...       
 Follow up   QTcF values of >450 ms    n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
   QTcF values of >4 80 ms   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
   QTcF values of >50 0 ms   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
        
 
PROGRAM SOURCE:### , DATA CUT OFF DATE: ddmmmyyyy   RUN DATE: ddmmyyy hh:mm CET  
  

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
TMP -SOP -0202 -001-03_SAP Template  Page 91/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  Zealand Pharma A/S  Clinical Study Report Section 14 
Protocol Number: ZP4207 -17086 Page 1 of x 
14.3.5.1.4: ECG, categorical analysis of QTc results , change from baseline , Safety analysis set  
 
Visit  
Time Point   
Result dasiglucagon  
(N=xxx) Placebo 
(N=xxx) GlucaGen  
(N=xxx) Total 
(N=xxx) 
        
 Dosing 20min post dose  QTcF CFB >30 ms   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
   QTcF CFB >60 ms   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
        
 Dosing 35min post dose  QTcF CFB >30 ms   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
   QTcF CFB >60 ms   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
        
 ...       
 Follow up   QTcF CFB >30 ms   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
   QTcF CFB >60 ms   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
        
 
PROGRAM SOURCE:### , DATA CUT OFF DATE: ddmmmyyyy   RUN DATE: ddmmyyy hh:mm CET  
 
Programmer Note: Baseline is the pre -dose result at  visit  1 Screening  
  

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
TMP -SOP -0202 -001-03_SAP Template  Page 92/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  Zealand Pharma A/S  Clinical Study Report Section 14 
Protocol Number: ZP4207 -17086 Page 1 of x 
14.3.5.2.1: Hematology , Safety analysis set  
Treatment  Visit n Mean Median SD Min Max CFB -Mean CFB- SD Below reference 
range  
n(%) Within reference 
range  
n(%) Above reference 
range  
n(%) 
Laboratory parameter test name 1  
   
dasiglucagon  Screening  xx xx.xx xx.xx xx.xxx xx.x xx.x - - n ( xx.x%)   n ( xx.x%)   n ( xx.x%)   
 Follow up  xx xx.xx xx.xx xx.xxx xx.x xx.x xx.xx xx.xxx n ( xx.x%)   n ( xx.x%)   n ( xx.x%)   
Placebo Screening  xx xx.xx xx.xx xx.xxx xx.x xx.x - - n ( xx.x%)  n ( xx.x%)   n ( xx.x%)   
 Follow up  xx xx.xx xx.xx xx.xxx xx.x xx.x xx.xx xx.xxx n ( xx.x%)   n ( xx.x%)   n ( xx.x%)   
Glucagon  Screening  xx xx.xx xx.xx xx.xxx xx.x xx.x - - n ( xx.x%)   n ( xx.x%)   n ( xx.x%)   
 Follow up  xx xx.xx xx.xx xx.xxx xx.x xx.x xx.xx xx.xxx n ( xx.x%)   n ( xx.x%)   n ( xx.x%)   
Total Screening  xx xx.xx xx.xx xx.xxx xx.x xx.x - - n ( xx.x%)   n ( xx.x%)   n ( xx.x%)   
 Follow up  xx xx.xx xx.xx xx.xxx xx.x xx.x xx.xx xx.xxx n ( xx.x%)   n ( xx.x%)   n ( xx.x%)   
   
Laboratory parameter test name 2  
   
dasiglucagon  Screening  xx xx.xx xx.xx xx.xxx xx.x xx.x - - n ( xx.x%)   n ( xx.x%)   n ( xx.x%)   
 Follow up  xx xx.xx xx.xx xx.xxx xx.x xx.x xx.xx xx.xxx n ( xx.x%)   n ( xx.x%)   n ( xx.x%)   
Placebo Screening  xx xx.xx xx.xx xx.xxx xx.x xx.x - - n ( xx.x%)   n ( xx.x%)   n ( xx.x%)   
 Follow up  xx xx.xx xx.xx xx.xxx xx.x xx.x xx.xx xx.xxx n ( xx.x%)   n ( xx.x%)   n ( xx.x%)   
Glucagon  Screening  xx xx.xx xx.xx xx.xxx xx.x xx.x - - n ( xx.x%)   n ( xx.x%)   n ( xx.x%)   
 Follow up  xx xx.xx xx.xx xx.xxx xx.x xx.x xx.xx xx.xxx n ( xx.x%)   n ( xx.x%)   n ( xx.x%)   
Total Screening  xx xx.xx xx.xx xx.xxx xx.x xx.x - - n ( xx.x%)   n ( xx.x%)   n ( xx.x%)   
 Follow up  xx xx.xx xx.xx xx.xxx xx.x xx.x xx.xx xx.xxx n ( xx.x%)   n ( xx.x%)   n ( xx.x%)   
...   
 
PROGRAM SOURCE:### , DATA CUT OFF DATE: ddmmmyyyy   RUN DATE: ddmmyyy hh:mm CET  
Programmer Note: Each laboratory test parameter is either displayed one per page or as shown here two on 1 page if possible.  
 
Zealand Pharma A/S  Clinical Study Report Section 14 
Protocol Number: ZP4207 -17086 Page 1 of x 
14.3.5.2.2: Clinical chemistry , Safety analysis set  
 

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
TMP -SOP -0202 -001-03_SAP Template  Page 93/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019   Repetiton of table 14.3.5.2.1 with different selection of the lab analysis dataset.  
  

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
TMP -SOP -0202 -001-03_SAP Template  Page 94/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  Zealand Pharma A/S  Clinical Study Report Section 14 
Protocol Number: ZP4207 -17086 Page 1 of x 
14.3.5.2.3: Coagulation , Safety analysis set  
 
 Repetiton of table 14.3.5.2.1 with different selection of the lab analysis dataset.  
  

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
TMP -SOP -0202 -001-03_SAP Template  Page 95/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  Zealand Pharma A/S  Clinical Study Report Section 14 
Protocol Number: ZP4207 -17086 Page 1 of x 
14.3.5.2.4: Urinalysis - pH, Safety analysis set  
 
 Repetiton of table 14.3.5.2.1 with different selection of the lab analysis dataset.  
  

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
TMP -SOP -0202 -001-03_SAP Template  Page 96/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  Zealand Pharma A/S  Clinical Study Report Section 14 
Protocol Number: ZP4207 -17086 Page 1 of x 
14.3.5.2.5: Urinalysis - quantitative results, count of abnormal results , Safety analysis set  
 
Urine parameter   
Visit  
Result dasiglucagon  
(N=xxx) Placebo 
(N=xxx) GlucaGen  
(N=xxx) Total 
(N=xxx) 
        
 Urine parameter 1  Screening  Below reference range    n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
   Within reference range    n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
   Above reference range    n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
        
  Dosing Below reference range    n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
   Within reference range    n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
   Above reference range   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
        
  Follow up  Below reference range    n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
   Within reference range    n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
   Above reference range    n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
        
 Urine parameter 2  Screening  Below reference range    n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
   Within reference range    n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
   Above reference range    n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
        
  Dosing Below reference range    n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
   Within reference range    n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
   Above reference range    n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
        
  Follow up  Below reference range    n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
   Within reference range    n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
   Above reference range    n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
        
 ...       
        
 
PROGRAM SOURCE:### , DATA CUT OFF DATE: ddmmmyyyy   RUN DATE: ddmmyyy hh:mm CET  
  

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
TMP -SOP -0202 -001-03_SAP Template  Page 97/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  Zealand Pharma A/S  Clinical Study Report Section 14 
Protocol Number: ZP4207 -17086 Page 1 of x 
14.3.5.2.6: Pregnancy tes t, Safety analysis set  
 
 
Visit  
Result dasiglucagon  
(N=xxx) Placebo 
(N=xxx) GlucaGen  
(N=xxx) Total 
(N=xxx) 
      
Screening  Negative    n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
 Positive    n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
      
Dosing Negative    n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
 Positive    n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
      
Follow up  Negative    n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
 Positive    n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
      
 
 
Screening : Serum pregnancy test  
Dosing,Follow up : Urine stick pregnancy test.  Prior to the start of the insulin -induced hypoglycemic procedure.  
 
PROGRAM SOURCE:### , DATA CUT OFF DATE: ddmmmyyyy   RUN DATE: ddmmyyy hh:mm CET  
  

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
TMP -SOP -0202 -001-03_SAP Template  Page 98/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019   
Zealand Pharma A/S  Clinical Study Report Section 14 
Protocol Number: ZP4207 -17086 Page 1 of x 
14.3.5.3: Local tolerability , Safety analysis set  
 
Local Symptom  Visit/ Time point  
Grade (Intensity)   
 dasiglucagon  
(N=xxx) Placebo 
(N=xxx) GlucaGen  
(N=xxx) Total 
(N=xxx) 
         
Spontaneous Pain  30min after dosing   None  xx ( xx.x)  xx ( xx.x)  xx ( xx.x)  xx ( xx.x)  
   Mild  xx ( xx.x)  xx ( xx.x)  xx ( xx.x)  xx ( xx.x)  
   Moderate   xx ( xx.x)  xx ( xx.x)  xx ( xx.x)  xx ( xx.x)  
   Severe  xx ( xx.x)  xx ( xx.x)  xx ( xx.x)  xx ( xx.x)  
         
 120min after dosing   None  xx ( xx.x)  xx ( xx.x)  xx ( xx.x)  xx ( xx.x)  
   Mild  xx ( xx.x)  xx ( xx.x)  xx ( xx.x)  xx ( xx.x)  
   Moderate   xx ( xx.x)  xx ( xx.x)  xx ( xx.x)  xx ( xx.x)  
   Severe  xx ( xx.x)  xx ( xx.x)  xx ( xx.x)  xx ( xx.x)  
         
 300min after dosing   None  xx ( xx.x)  xx ( xx.x) xx ( xx.x)  xx ( xx.x)  
   Mild  xx ( xx.x)  xx ( xx.x)  xx ( xx.x)  xx ( xx.x)  
   Moderate   xx ( xx.x)  xx ( xx.x)  xx ( xx.x)  xx ( xx.x)  
   Severe  xx ( xx.x)  xx ( xx.x)  xx ( xx.x)  xx ( xx.x)  
         
 Follow up   None  xx ( xx.x)  xx ( xx.x)  xx ( xx.x)  xx ( xx.x)  
   Mild  xx ( xx.x)  xx ( xx.x)  xx ( xx.x)  xx ( xx.x)  
   Moderate   xx ( xx.x)  xx ( xx.x)  xx ( xx.x)  xx ( xx.x)  
   Severe  xx ( xx.x)  xx ( xx.x)  xx ( xx.x)  xx ( xx.x)  
         
 
 
Percentages are b ased on total no. of subjects in each treatment group  
 
PROGRAM SOURCE:### , DATA CUT OFF DATE: ddmmmyyyy   RUN DATE: ddmmyyy hh:mm CET  
 
Programmer Note: Table is produced with same SAS macro like Aes (npcttab).  
  

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
TMP -SOP -0202 -001-03_SAP Template  Page 99/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  Zealand Pharma A/S  Clinical Study Report Section 14 
Protocol Number: ZP4207 -17086 Page 1 of x 
14.3.5.4: Vital signs , Safety analysis set  
 
 
Parameter   
Visit/Time Point   
Result dasiglucagon  
(N=xxx) Placebo 
(N=xxx) GlucaGen  
(N=xxx) Total 
(N=xxx) 
   
Screening       
 Systolic blood 
pressure [mmHg]  n xx xx xx xx 
   Mean (SD)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  
   Median xx.x xx.x xx.x xx.x 
   Min, Max  xx, xx xx, xx xx, xx xx, xx 
        
  Dosing/ Prior start of hypoglycemic procedure  n xx xx xx xx 
   Mean (SD)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx) xx.x (xx.xx)  
   Median xx.x xx.x xx.x xx.x 
   Min, Max  xx, xx xx, xx xx, xx xx, xx 
        
  Dosing/ 30min post dose  n xx xx xx xx 
   Mean (SD)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  
   Median xx.x xx.x xx.x xx.x 
   Min, Max  xx, xx xx, xx xx, xx xx, xx 
        
        
 ...       
        
  Follow up  Mean (SD)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  
   Median xx.x xx.x xx.x xx.x 
   Min, Max  xx, xx xx, xx xx, xx xx, xx 
   n xx xx xx xx 
        
 
PROGRAM SOURCE:### , DATA CUT OFF DATE: ddmmmyyyy   RUN DATE: ddmmyyy hh:mm CET  
Programmer Note: This table is continued for each of the following Vital signs parameter: Systolic blood pressure  [mmHg ], Pulse rate [bpm ] and 
body temparature [°C]  
  

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
TMP -SOP -0202 -001-03_SAP Template  Page 100/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  Zealand Pharma A/S Clinical Study Report Section 14 
Protocol Number: ZP4207 -17086 Page 1 of x 
14.3.5.5 : Pulse rate  - categorical analysis , Safety analysis set  
 
Visit  
Time Point   
Class dasiglucagon  
(N=xxx) GlucaGen  
(N=xxx) Placebo 
(N=xxx) Total 
(N=xxx) 
        
 Screening   Class1   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
   Class2   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
        
 Dosing Prior start of hypoglycemic procedure  Class1   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
   Class2   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
        
 Dosing 30min post dose  Class1   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
   Class2   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
        
        
 ...       
        
 Follow up   Class1   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
   Class2   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
        
 
PROGRAM SOURCE:### , DATA CUT OFF DATE: ddmmmyyyy   RUN DATE: ddmmyyy hh:mm CET 
Programmer Note: This table is repeated (as byvars) for each of the following Vital signs parameter: Systolic blood pressure  [mmHg], Pulse rate 
[bpm] and body temparature [°C]  
  

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
TMP -SOP -0202 -001-03_SAP Template  Page 101/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019   
 
Zealand Pharma A/S  Clinical Study Report Section 14 
Protocol Number: ZP4207-17086 Page 1 of 1 
14.3.5.6: Immunogenicity - occurrence of ADA , Safety analysis set  
 
 dasiglucagon  
(N=xxx) Placebo 
(N=xxx) GlucaGen  
(N=xxx) Total 
(N=xxx) 
 
Occurrence of ADA  
 No   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
Yes   n ( xx.x%)     n ( xx.x%)     n ( xx.x%)     n ( xx.x%)   
 Missing   n             n             n             n           
      
 
 
PROGRAM SOURCE:### , DATA CUT OFF DATE: ddmmmyyyy  RUN DATE: ddmmyyy hh:mm CET  
 
  

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
TMP -SOP -0202 -001-03_SAP Template  Page 102/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  Zealand Pharma A/S  Clinical Study Report Section 14 
Protocol Number: ZP4207 -17086 Page 1 of 1 
14.4.1.1 : Summary statistics of plasma dasiglucagon and GlucaGen concentration table , FAS 
 
Treatment   
Variable   Pre- 
dose 10min 20min 30min  
40min  
60min  
90min  
140min  
220min  
300min 
              
 Glucagon  Result n  xx xx xx xx xx xx xx xx xx 
   Mean (SD)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  
   Median xx.x xx.x xx.x xx.x xx.x xx.x xx.x xx.x xx.x xx.x 
   Min, Max  xx, xx xx, xx xx, xx xx, xx xx, xx xx, xx xx, xx xx, xx xx, xx xx, xx 
              
  Change from baseline  n  xx xx xx xx xx xx xx xx xx 
   Mean (SD)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx) xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  
   Median xx.x xx.x xx.x xx.x xx.x xx.x xx.x xx.x xx.x xx.x 
   Min, Max  xx, xx xx, xx xx, xx xx, xx xx, xx xx, xx xx, xx xx, xx xx, xx xx, xx 
              
 dasiglucagon  Result n  xx xx xx xx xx xx xx xx xx 
   Mean (SD)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  
   Median xx.x xx.x xx.x xx.x xx.x xx.x xx.x xx.x xx.x xx.x 
   Min, Max  xx, xx xx, xx xx, xx xx, xx xx, xx xx, xx xx, xx xx, xx xx, xx xx, xx 
              
  Change from baseline  n  xx xx xx xx xx xx xx xx xx 
   Mean (SD)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx) 
   Median xx.x xx.x xx.x xx.x xx.x xx.x xx.x xx.x xx.x xx.x 
   Min, Max  xx, xx xx, xx xx, xx xx, xx xx, xx xx, xx xx, xx xx, xx xx, xx xx, xx 
              
 
Pre-dose results LLOQ are set to 0 pmol/mL  
Results are rounded to 3 significant digits  
 
PROGRAM SOURCE:### , DATA CUT OFF DATE: ddmmmyyyy   RUN DATE: ddmmyyy hh:mm CET  
Programmer Note: The mean (SD) column above is broken into 2 lines above, but if possible put it in one row  
 
  
Zealand Pharma A/S  Clinical Study Report Section 14 
Protocol Number: ZP4207 -17086 Page 1 of x 
14.4.1.2 : PK metrics , FAS 
 
 

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
TMP -SOP -0202 -001-03_SAP Template  Page 103/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  PK Parameter   dasiglucagon  
(N=xxx) GlucaGen  
(N=xxx) Total 
(N=xxx) 
      
 Cmax [pmol/L]  n xx xx xx 
  Mean (SD)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  
  Median xx.x xx.x xx.x 
  Min, Max  xx, xx xx, xx xx, xx 
  Geom. Mean  xx, xx xx, xx xx, xx 
  Gem. Mean CV %  xx, xx xx, xx xx, xx 
      
 Tmax [h]  n xx xx xx 
  Mean (SD)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  
  Median xx.x xx.x xx.x 
  Min, Max  xx, xx xx, xx xx, xx 
 ...     
      
 
 
Results are rounded to 3 significant digits  
 
PROGRAM SOURCE:### , DATA CUT OFF DATE: ddmmmyyyy   RUN DATE: ddmmyyy hh:mm CET  
  

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
TMP -SOP -0202 -001-03_SAP Template  Page 104/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  Zealand Pharma A/S  Clinical Study Report Section 14 
Protocol Number: ZP4207 -17086 Page 1 of x 
14.4.1.3 : Figure: Mean analy te concentrations versus time - original scale , FAS 
 
 
 
 
 
PROGRAM SOURCE:### , DATA CUT OFF DATE: ddmmmyyyy   RUN DATE: ddmmyyy hh:mm CET  
NOTE: This is a generic example using example data not real data  
  


 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
TMP -SOP -0202 -001-03_SAP Template  Page 105/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  Zealand Pharma A/S  Clinical Study Report Section 14 
Protocol Number: ZP4207 -17086 Page 1 of x 
14.4.1.4 : Figure: Mean analy te concentrations versus time - log scale, FAS 
 
 Repetiton of figure 14.4.1.3 using logarithmic y -scale 
 
 
 

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
TMP -SOP -0202 -001-03_SAP Template  Page 106/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019   
Zealand Pharma A/S  Clinical Study Report Section 14 
Protocol Number: ZP4207-17086 Page 1 of x 
14.4.1.5: Figure: Individual analyte concentrations versus time curves - original scale , FAS 
 
 
PROGRAM SOURCE:### , DATA CUT OFF DATE: ddmmmyyyy   RUN DATE: ddmmyyy hh:mm CET  
NOTE: This is a generic example using example data not real data  and coloring will be the same as in the figure before; x -axis and sampling scheme 
will be adapted to the study specifics  
  


 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
TMP -SOP -0202 -001-03_SAP Template  Page 107/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  Zealand Pharma A/S  Clinical Study Report Section 14 
Protocol Number: ZP4207 -17086 Page 1 of x 
14.4.2.1 : PD metrics , FAS 
 
 
PK Parameter   dasiglucagon  
(N=xxx) Placebo 
(N=xxx) GlucaGen  
(N=xxx) Total 
(N=xxx) 
       
 Cmax [pmol/L]  n xx xx xx xx 
  Mean (SD)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  
  Median xx.x xx.x xx.x xx.x 
  Min, Max  xx, xx xx, xx xx, xx xx, xx 
       
 Tmax [h]  n xx xx xx xx 
  Mean (SD)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  xx.x (xx.xx)  
  Median xx.x xx.x xx.x xx.x 
  Min, Max  xx, xx xx, xx xx, xx xx, xx 
 ...      
       
 
 
 
PROGRAM SOURCE:### , DATA CUT OFF DATE: ddmmmyyyy   RUN DATE: ddmmyyy hh:mm CET  
  

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
TMP -SOP -0202 -001-03_SAP Template  Page 108/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  Zealand Pharma A/S  Clinical Study Report Section 14 
Protocol Number: ZP4207 -17086 Page 1 of x 
14.4.2.2 : Figure: Mean glucose concentrations versus time - original scale , FAS 
 
 
 Repetiton of figure 14.4.1.3 using glucose concentration and adapted sampling scheme  
  

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
TMP -SOP -0202 -001-03_SAP Template  Page 109/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019  Zealand Pharma A/S  Clinical Study Report Section 14 
Protocol Number: ZP4207 -17086 Page 1 of x 
14.4.2.3 : Figure: Individual glucose concentrations versus time curves - original scale , FAS 
 
 
 Repetiton of figure 14.4.1.4 using glucose concentration and adapted sampling scheme  
 
 
 
 

 
 
 
Zealand Pharma A/S                                                                                                    Statistical Analysis Plan  
ZP4207 -1708 6 (ZEA -DNK -02170)   16 August 2019  
TMP -SOP -0202 -001-03_SAP Template  Page 110/110 
CONFIDENTIAL  
ZEA -DNK -02170_SAP_Vers.1.0_clean_16AUG2019   
Appendix E: Listing Layouts  
 
Zealand Pharma A/S  Clinical Study Report Section 16.2 
Protocol Number: ZP4207 -17086 Page 1 of x 
 
 
 
 
Listing 16.2.x 
Title, Population (if applicable)  
 
 
Treatment  Subject  
ID Parameter  Visit Time Point  Variable  1 Variable  2 Variable  3 Variable  4 Variable xxxx  
xxx xxx xxx xxx xxx xxx xxx xxx xxx xxx 
          
 
 
 
 
 
 
PROGRAM SOURCE:### , DATA CUT OFF DATE: ddmmmyyyy   RUN DATE: ddmmyyy hh:mm CET  
 
 
 
 
 
 
Programmer Note:  
- Listings are sorted by treatment, Subject ID, Parameter, Visit and timepoint as applicable and available.  
- Listings usually will display all data avaiölable and not restricted to any analysis set if not defined otherwise in  the SAP  
 

